MXPA06009860A - Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof - Google Patents

Abstract

The present invention provides cyclic nitrogen-containing fused derivatives represented by the following general formula or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, glucose intolerance, diabetic complications or obesity, in formula one of R1 and R4 represent a group represented by the following general formula (S) (wherein R5 and R6 represent H, OH, a halogen atom, etc., Q represents an alkylene group, etc., and ring A represents an aryl group, etc.), and the others represent H, OH, an amino group, etc. R2 and R3 represent H, OH, an amino group, a halogen atom, and an optionally substituted alkyl group, etc., A1 represents O, S, etc., A2 represents CH or N, G represents a group represented by or by the following general formula (G-1) or (G-2) (E1 represents H, F or OH, and E2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof. (see formulas (I), (S), (G-1) and (G-2)

Description

HETEROCICLIC FUSED DERIVATIVE. MEDICINAL COMPOSITION THAT CONTAINS THE SAME. AND MEDICAL USE OF THE SAME Field of the Invention The present invention relates to heterocyclic derivatives, pharmaceutically acceptable salts thereof or prodrugs thereof, which are useful as medicaments, pharmaceutical compositions comprising the same and to pharmaceutical uses thereof. More particularly, the present invention relates to fused heterocyclic derivatives having an inhibitory activity on human SGLT, pharmaceutically acceptable salts thereof or prodrugs thereof, which are useful as agents for the prevention or treatment of a disease associated with hypergiukaemia. , such as diabetes, glucose intolerance, diabetic complication or obesity, to pharmaceutical compositions comprising the same and pharmaceutical uses thereof. Background of the Invention Diabetes is one of lifestyle-related diseases with a history of changes in eating habits and lack of exercise. Therefore, diet and exercise therapies are carried out in patients with diabetes. In addition, when its sufficient control and continuous performance are difficult, the Drug treatment is carried out simultaneously. In addition, it has been confirmed through large-scale clinical trials that it is necessary to carry out a strict long-term control of the blood sugar level in order to avoid that patients with diabetes, when receiving treatment, have emergence and progression of diabetic complications (for example, see the following References 1 and 2). In addition, many epidemiological studies with respect to impaired glucose tolerance and macroangiopathy show that glucose intolerance as the limit type is also a risk factor in macroangiopathy as well as diabetes. Therefore, the need to improve postprandial hyperglycemia has been addressed (see for example the following Reference 3). In recent years, the development of several antidiabetic agents has progressed, with the history of a rapid increase in patients with diabetes. For example, antidiabetic agents have been used, such as biguanides, sulfonylureas, insulin sensitivity enhancers, α-glucosidase inhibitors and the like. However, biguanides and sulfonylureas occasionally show adverse effects, such as lactic acidosis and hypoglycaemia, respectively. Insulin sensitivity enhancers occasionally show adverse effects such as edema, and are responsible for the progression of obesity. In addition, alpha-glucosidase inhibitors, which delay carbohydrate digestion and absorption in the small intestine, are used to improve postprandial hyperglycemia. It has also been reported that acarbose, one of the a-glucosidase inhibitors, has an effect in the prevention or delay of the incidence of diabetes, being applied to patients with glucose intolerance (for example, see the following Reference 4). However, since a-glucosidase inhibitors do not affect elevated glucose levels by ingesting a glucose monosaccharide (eg, see Reference 5 below) with sugar compositions of recent change in foods, greater range of activities that inhibit the absorption of carbohydrates. In recent years, the research and development of new types of antidiabetic agents has progressed, which promotes the excretion of urinary glucose and the lower blood glucose level, preventing the reabsorption of excess glucose in a kidney (for example, see the following Reference 6). In addition, it is reported that SGLT2 (sodium-dependent glucose transporter 2) is found in segment S 1 of the proximal tubule of the kidney and participates mainly in glucose reabsorption filtered through the glomerular (see for example the following Reference 7). Accordingly, the inhibition of a human SGLT2 activity, prevents the reabsorption of excess glucose in the kidney, subsequently promotes the excretion of excess glucose through the urine, and normalizes the blood glucose level. In addition, since said agents to promote the excretion of urinary glucose, excrete excess glucose through the urine and consequently the Glucose accumulation in the body is decreased, it is also expected to have a preventive or relief effect on obesity and a diuretic effect. In addition, the agents are considered as useful for various related diseases which occur accompanying the progress of diabetes or obesity due to hypergiukaemia. In addition, it is known that SGLT1, the sodium-dependent glucose transporter 1, exists in the small intestine, which controls the absorption of carbohydrate. It has also been reported that insufficiency of glucose and galactose uptake arises in patients with dysfunction due to congenital abnormalities of human SGLT1 (for example, see References 8-10 below). In addition, it has been confirmed that SGLT1 is involved in the absorption of glucose and galactose (for example, see the following References 1 1 and 12). In addition, it has been confirmed that it increases the mRNA and protein of SGLT1 and accelerates the absorption of glucose in OLEFT rats and rats with diabetic symptoms induced by streptozotocin (for example, see the following References 13 and 14). Generally in patients with diabetes, digestion and absorption of carbohydrates are increased. For example, it is confirmed that the mRNA and the SGLT1 protein are greatly increased in the human small intestine (for example, see the following Reference 15). Accordingly, blockade of a human SGLT1 activity inhibits the absorption of carbohydrates, such as glucose in the small intestine, subsequently can prevent the increase in blood sugar level. Especially, it is considered that the delay of the absorption of glucose based on the aforementioned mechanism is effective to normalize the postprandial hypergiucemia. Accordingly, a rapid development of antidiabetic agents with a novel mechanism of action, which has an inhibitory activity in human SGLT, is needed to improve or solve the aforementioned problems. The fused heterocyclic derivatives provided in the present invention are completely novel compounds. It had not been reported, that these derivatives had inhibitory activities in SGLT1 and / or SGLT2, and that they inhibited the absorption of glucose and galactose in the small intestine, or were useful as agents to inhibit the reabsorption of excess glucose in the kidney. Reference 1: The Diabetes Control and Complications Trial Research Group, N. Engl. J. Med., 1993.9, Vol. 329, No.14, pages 977-986; Reference 2: UK Prospective Diabetes Study Group, Lancet, 1998. 9, Vol. 352, No. 9131, pages 837-853; Reference 3: Makoto TOMI NAGA, Endocrinology & Diabetology, 2001 .1 1, Vol. 13, No. 5, pages 534-542; Reference 4: Jean-Louis Chiasson and 5- persons, Lancet, 2002. 6, Vol. 359, No. 9323, pages 2072-2077; Reference 5: Hiroyuki ODAKA and 3 persons, Journal of Japanese Society of Nutrition and Food Science, 1992, Vol. 45, page 27; Reference 6: Luciano Rossetti and 4 people, J. Clin. Invest., 198J.5, Vol.79, pages 1510-1515; Reference 7: Yoshikatsu Kanai and 4 people, J. Clin. Invest., 1994.1, Vol.93, pages 397-404; Reference 8: Tadao BABA and 1 person, Supplementary volume of Nippon Rinsho, Ryoikibetsu Shokogun, 1998, No. 19, pages 552-554; Reference 9: Michihiro KASAHARA and 2 people, Saishin Igaku, 1996.1, Vol. 51, No. 1, pages 84-90; Reference 10: Tomofusa TSUCHIYA and 1 person, Nippon Rinsho, 1997. 8, Vol. 55, No. 8, pages 2131-2139; Reference 11: Yoshikatsu KANAI, Kidney and Dialysis, 1998.12, Vol. 45, extra edition, pages 232-237; Reference 12: E. Turk and 4 people, Nature, 1991.3, Vol. 350, pages 354-356; Reference 13: Y. Fujita and 5 people, Diabetologia, 1998, Vol. 41, pages 1459-1466; Reference 14: J. Dyer and 5 people, Biochemical Society Transactions, 1997, Vol.25, page 479S; Reference 15: J. Dyer and 4 people, American Journal of Physiology, 2002. 2, Vol.282, No.2, pages G241-G248. Description of the Invention The inventors of the present invention have studied until they find compounds that have an inhibitory activity in SGLT human. As a result, it was found that certain fused heterocyclic derivatives represented by the following general formula (I), show an inhibitory activity in human SGLT1 and / or SGLT2 and are excellent agents that have inhibitory activity in the increase of blood glucose level or decrease in the blood glucose level, as will be shown below, thus forming the bases of the present invention. The present invention provides novel compounds which exhibit an inhibitory activity in SGLT, pharmaceutical compositions comprising the same and pharmaceutical uses thereof. That is, the present invention relates to: (1) a fused heterocyclic derivative represented by the following general formula (I): wherein: one of R1 and R4 represents a group represented by the general formula: R5 \ Q-Í A) (S) [in the formula R5 and R6 independently represent a hydrogen atom, a hydroxy group, a halogen atom, a C -? --6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C- group ? -6 alkoxy, a C2-6 alkenyloxy group, a C-? -6 alkylthio group, a C2-6 alkenylthio group, a halo (C? -6 alkyl) group, a halo (C1-6 alkoxy) group, a halo group (C-6 alkylthio), a hydroxy group (C-? 6 alkyl), a hydroxy group (C 2-6 alkenyl), a hydroxy group (C 1-6 alkoxy), a hydroxy group (C? -6) alkylthio), a carboxy group, a carboxy group (C? .T alkyl), a carboxy group (C2.6 alkenyl), a carboxy group (C? -6 alkoxy), a carboxy group (C1-6 alkylthio), an alkoxycarbonyl group, a C2-7 alkoxycarbonyl group (C -? - 6 alkyl), a C2-7 alkoxycarbonyl group (C2-6 alkenyl), a C2-7 alkoxycarbonyl group (C2-6 alkoxy), a C2-7 group alkoxycarbonyl (C 1-6 alkylthio), a C -? - 6 alkylsulfinyl group, a C? -6 alkylsulfonyl group, -UVWN (R7) -Z, or any of the substi listeners of (i) to (xxviii) below, which may have 1 to 3 substituents selected from the following substituent group on the ring; (i) a C6-? or aryl group, (ii) C6-1 0 aryl-O-, (iii) C6-? or aryl-S-, (iv) a C6-? or aryl (C1-6 alkyl) group, (v) a C6-10 aryl group (C? -6 alkoxy), (vi) a C6-? or aryl (C? -6 alkylthio), (vii) a heteroaryl group, (viii) heteroaryl-O-, (ix) heteroaryl-S-, (x) a heteroaryl group (C 1-6 alkyl), (xi) a heteroaryl group (C1 -6 alkoxy), (xii) a heteroaryl group (C1-6 alkylthio), (xiii) a C3-7 cycloalkyl group, (xiv) C3-7 cycloalkyl-O-, (xv) C3-7 Cycloalkyl-S-, (xvi) a group cycloalkyl (C6-6 alkyl), (xvii) C3-7 cycloalkyl (C6-alkoxy), (xviii) a C3-7 cycloalkyl group (C6-6 alkylthio), (xix) a heterocycloalkyl group, (xx) ) heterocycloalkyl-O-, (xxi) heterocycloalkyl-S-, (xxii) a heterocycloalkyl group (C 1-6 alkyl), (xxiii) a heterocycloalkyl group (C 1-6 alkoxy), (xxiv) a heterocycloalkyl group (Ci. alkylthio), (xxv) an aromatic cyclic amino group, (xxvi) an aromatic cyclic amino group (C- | .6 alkyl) or (xxvii) an aromatic cyclic amino group (C -? - 6 alkoxy), (xxviii) a aromatic cyclic amino group (C 1-6 alkylthio), J represents a C 1-6 alkylene group, which may have a hydroxy group, or a C 2-6 alkenylene group; U represents -O-, -S-, or a single bond, provided that at least one of V and W is not a single bond when U is -O- or -S- V represents a group C? "6 alkylene, the which may have a hydroxy group, a C 2-6 alkenylene group or a single bond; W represents -CO-, -SO2-, -C (= N H) - or a single bond; Z independently represents a hydrogen atom, a C2-7 alkoxycarbonyl group, a C6-? or aryl (C2-7 alkoxycarbonyl), a formyl group, -RA, -CORB, -SO2RB, -CON (Rc) RD, -CSN (RC) RD, -SO2NH RA or -C (= N RE) N (RF) RG; R7, RA, Rc, and RD independently represent a hydrogen atom, a C1-6 alkyl group, which may have from 1 to 5 substituents selected from the following substituent group β, or any of the following substituents of (xxix) al (xxxii) that they may have from 1 to 3 substituents selected from the following substituent group; (xxix) a group C6-? or aryl, (xxx) a heteroaryl group, (xxxi) a C3-7 cycloalkyl group, or (xxxii) a heterocycloalkyl group, or Z and R7 bond together with the surrounding nitrogen atom to form an aliphatic cyclic amino group, which may have from 1 to 3 substituents selected from the following group a substituent; or Rc and RD link together with the surrounding nitrogen atom to form an aliphatic cyclic amino group which may have from 1 to 3 substituents selected from the following substituent group; RB represents a C2-7 alkoxycarbonyl group, a C1-6 alkylsulfonylamino group, a C6-? or arylsulfonylamino, a C1-6 alkyl group, which may have from 1 to 5 its substituents selected from the following substituent group, or any of the following substituents (xxxiii) a (xxxvi) which may have from 1 to 3 substituents selected from the following group to substituent; (xxxiü) a C6-? or aryl group, (xxxiv) a heteroaryl group, (xxxv) a C3-7 cycloalkyl group, or (xxxvi) a heterocycloalkyl group, RE, RF, and RG independently represent a hydrogen atom, a cyano group, a carbamoyl group, a C2-7 acyl group, a C2-7 alkoxycarbonyl group, a C6-? or aryl (C2-alkoxycarbonyl), a nitro group, a C1_6 alkylsulfonyl group, a sulfamide group, a carbamimidoyl group, or a C1_6 alkyl group, which may have from 1 to 5 substituents selected from the following substituent group ß; or RE and RF link together to form an ethylene group; or RF and RG bond together with the surrounding nitrogen atom to form an aliphatic cyclic amino which may have any substituent selected from the following substituent group; Q represents -C? -6 alkylene-, -C2-6 alkenylene-, -C2-6 alkynylene-, -C1-6 alkylene-O-, -C? _6 alkylene-S-, -OC -6alkylene, -SC? -6 alkylene-, -C6 alkylene-OC-6-alkylene-, -C6-6 alkylene-S-C1-6 alkylene-, -CON (R8) -, -N (R8) CO- , -C1 -6 alkylene-CON (R8) - or - CON (R8) -C1 -6 alkylene-; R8 represents a hydrogen atom or a C1-C6 alkyl group; ring A represents a group C6-? or aryl or a heteroaryl group] and the others represent a hydrogen atom, a hydroxy group, an amino group, a halogen atom, a d-6 alkyl group, a C-α-6 alkoxy group, a cyano group, a carboxy group, a C 2-7 alkoxycarbonyl group, a carbamoyl group, a mono- or di (C 1-6 alkyl) amino group, a halo (C 1-6 alkyl) group, a hydroxy group (C? -6 alkyl), a group cyano (C 1-6 alkyl), a carboxy (C 1-6 alkyl) group, a C 2-7 alkoxycarbonyl group (C 1-6 alkyl), a carbamoyl group (C 1-6 alkyl), an amino group (C 1-6) alkyl), a mono or di (C 1-6 alkyl) amino (C 1-6 alkyl) group, a halo (C -? - 6 alkoxy) group, a hydroxy group (C? -6 alkoxy), a carboxy group ( C1 -6 alkoxy), a C2-alkoxycarbonyl group (C -? - 6 alkoxy), a carbamoyl group (C1-6 alkoxy), an amino group (C1-6 alkoxy), a mono- or di- (C1-6 alkyl) group ) amino (Ci. 6 alkoxy), a C3-7 cycloalkyl group, a C3-7 cycloalkyloxy group, a C3-7 cycloalkyl group (C? -6 alkyl), or a C3-7 cycloalkyl group (C? -6 alkoxy); R2 and R3 independently represent a hydrogen atom, a hydroxy group, an amino group, a halogen atom, a C? -6 alkyl group, a C? -6 alkoxy group, a cyano group, a carboxy group, a C2 group .7 alkoxycarbonyl, a carbamoyl group, a mono- or di- (C 1-6 alkyl) amino group, a halo (C 1-6 alkyl) group, a hydroxy group (C? -6 alkyl), a cyano group (C? 6 alkyl), a carboxy (C1-6 alkyl) group, a C2-7 alkoxycarbonyl group (C -6 alkyl), a carbamoyl group (C-? -6 alkyl), an amino group (C1-6 alkyl), a mono- or di- (C 1-6 alkyl) amino (C 1-6 alkyl) group, a halo (C 1-6 alkoxy) group, a hydroxy (C 1-6 alkoxy) group, a carboxy (C- | 6 alkoxy) group, a group 'C 2-7 alkoxycarbonyl (C 1-6 alkoxy), a carbamoyl group (C 1-6 alkoxy), an amino group (C 1-6 alkoxy), a mono- or di (C 1-6 alkyl) amino group (C? 6) alkoxy), a C3-7 cycloalkyl group, a C3-7 cycloalkylloxy group, a C3-7 cycloalkyl group (C1-6 alkyl), or a C3-7 cycloalkyl group (C1 -6 alkoxy); A1 represents O, S, or N R9; A2 represents CH or N; R9 represents a hydrogen atom or a C1-6 alkyl group; G represents a group represented by a formula: (G- l) or a formula: E1 represents a hydrogen atom, a fluorine atom or a hydroxy group; E2 represents a hydrogen atom, a fluorine atom, or a methyl group or a hydroxymethyl group; [group its bituant a] a halogen atom, a hydroxy group, an amino group, a C? _6 alkyl group, a C? -6 alkoxy group, a halo group (C? -6 alkyl), a halo group (C1) -6 alkoxy), a hydroxy group (C -6 alkyl), a C2-7 alkoxycarbonyl group (C-? -6 alkyl), a hydroxy group (C1-6 alkoxy), an amino group (C -6 alkyl), a (C 1-6 alkoxy) amino group, a mono- or di (C-? - 6 alkyl) amino group, a mono- or di- [hydroxy (C? -6 alkyl)] amino group, a C 1-6 alkylsulfonyl group, a group C-6 alkylsulfonylamino, a group C1 -6 alkylsulfonylamino (C1-6 alkyl), a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group, and -CON (RH) R \ [substituent group β] an atom of halogen, a hydroxy group, an amino group, a C -? - 6 alkoxy group, a C? _6 alkylthio group, a halo (C1-6 alkoxy) group, a group (C -6 alkylthio), a hydroxy group (C- .6 alkoxy), a hydroxy group (C -? - 6 alkylthio), a (C 1-6 alkoxy) amino group, an amide group (C? -6 alkylthio), a mono- or di (C1) group - 6 alkyl) amino, a group mono or di [hydroxy (C-6 alkyl)] amino, a ureido group, a sulfonamide group, a mono- or di (C? -6 alq uyl) ureido group, a mono- or di [hydroxy (C1 -6 alkyl) group) ] ureido, a mono- or di (C -6alkyl) sulfonamide group, a mono- or di [hydroxy (C1-6alkyl)] -sulfonamide group, a C2-7acylamino group, an amino group (C2-acylamino), a group C1 -6 alkylsulfonyl, a C -6 alkylsulfonylamino group, a carbamoyl group (C-α-6 alkylsulfonylamino), a carboxy group, a C2-alkoxycarbonyl group, -CON (RH) R \ and any of the following substituents of (xxxvii ) to (xxxxviii), which may have from 1 to 3 substituents selected from the above substituent group. (xxxvii) a C6-? or aryl group, (xxxviii) C6-? or aryl-O-, (xxxix) a Ce-10 aryl group (C1-6 alkoxy), (xxxx) a C6-? or aryl (C1 -6 alkylthio), a group (xxxxi) a heteroaryl group, (xxxxii) heteroaryl-O-, (xxxxiii) a C3-7 cycloalkyl group, (xxxxiv) C3-7 cycloalkyl-O-, (xxxxv) a heterocycloalkyl group, (xxxxvi) heterocycloalkyl-O-, (xxxxvii) an aliphatic cyclic amino group or (xxxxviii) an aromatic cyclic group, RH and R1 independently represent a hydrogen atom or a C-α-6 alkyl group, which Can you have 1 to 3 substituents selected from the following group? substituent; or both RH and R1 bond together with the surrounding nitrogen atom to form an aliphatic cyclic amino group which may have from 1 to 3 its constituents selected from the following substituent group d; [group? substituent] a halogen atom, a hydroxy group, an amino group, a C? -6 alkoxy group, a halo (C1-6 alkoxy) group, a hydroxy (C-? -6 alkoxy), an amino group (C1 -6 alkoxy), a mono- or di (C-? 6 alkyl) amino group, a mono- or di- [hydroxy (C? -6 alkyl)] amino group, a ureido group, a sulfamide group, a mono or di group ( C 1-6 alkyl) ureido, a mono or di [hydroxy (C 1-6 alkyl)] ureido group, a mono- or di (C-6 alkyl) sulfamide group, a mono or di [hydroxy (C? -6 alkyl) group) ] sulfonamide, a C2-7 acylamide group, an amino group (C2-7 acylamino), a C- | .6 alkylsulfonyl group, a C ^ ß alkylsulfonylamino group, a carbamoyl group (C? -6 alkylsulfonylamino), a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group, and -CON (RJ) R ?, [substituent group D] a halogen atom, a hydroxy group, an amino group, a C -? - 6 alkyl group, a C 1-6 alkoxy group, a halo group (C? -6 alkyl), a halo group (C-6 alkoxy) a hydroxy group (Ci-β) alkyl) a group C 2-7 alkoxycarbonyl (d-6alkyl), a hydroxy group (C 1-6 alkoxy), an amino group (d-βalkyl), an amino group (C-α-6alkoxy), a mono- or di (C1) group -6 alkyl) amino, a mono or di [hydroxy (C-α-6 alkyl)] amino group, a C 1-6 alkylsulfonyl group, a C 1-6 alkylsulfonylamino group, a C 1-6 alkylsulfonylamino group (C-6 alkyl) , a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group, and -CON (RJ) R ?, RJ and R? independently represent a hydrogen atom or a d-6 alkyl group, which may have any of 1 to 3 substituents selected from a hydroxy group, an amino group, a mono- or d- (d-6-alkyl) amino group, a C2-7 alkoxycarbonyl group, and a carbamoyl group; or both R and R? they bond together with the surrounding nitrogen atom to form an aliphatic cyclic amino group which may have any of 1 to 3 substituents selected from a hydroxy group, an amino group, a mono- or di (C1-alkyl) amino group, a d.6 alkyl group, a hydroxy (d-6 alkyl) group, a C2.7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl (C1-6 alkyl) group, and a carbamoyl group, or a pharmaceutically acceptable salt thereof , or a prodrug thereof; [2] a fused heterocyclic derivative as described in [1] above, wherein Q represents a methylene group, an ethylene group, -OCH2-, -CH2O-, -SCH2-, or -CH2S-, or a salt pharmaceutically acceptable thereof, or a prodrug thereof; [3] a fused heterocyclic derivative as described in [2] above, wherein Q represents a ethylene group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof; [4] a fused heterocyclic derivative as described in [2] above, wherein Q represents a methylene group or a pharmaceutically acceptable salt thereof, or a prodrug thereof; [5] a fused heterocyclic derivative as described in [1] above, wherein R5 and R6 independently represent a hydrogen atom, a hydroxy group, a halogen atom, a d-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C 1-6 alkoxy group, a C 2-6 alkenyl group, a C 1-6 alkylthio group, a C 2-6 alkenylthio group, a halo (C 1-6 alkyl) group, a halo (C 1-6 alkoxy) group, a halo group (C 1-6 alkylthio), a hydroxy group (C 1-6 alkyl), a hydroxy group (C 2-6 alkenyl), a hydroxy group (C 1-6 alkoxy), or a hydroxy group (C 1-6 alkylthio), or a pharmaceutically acceptable salt thereof, or a prodrug thereof; [6] a fused heterocyclic derivative as described in any of [1] to [5] above, wherein ring A represents a benzene ring or a pyridine ring, or a pharmaceutically acceptable salt thereof, or a prodrug of the same; [7] a fused heterocyclic derivative as described in any of [1] to [6] above, wherein G represents a group represented by the formula: , or a pharmaceutically acceptable salt thereof, or a prodrug thereof; [8] a pharmaceutical composition comprising as an active ingredient, a fused heterocyclic derivative such as describes in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof; [9] a human SGLT inhibitor comprising as an active ingredient a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof; [1 0] a human SGLT inhibitor as described in [9] above, wherein the SGLT is SGLT1 and / or SGLT2; [1 1] a human SGLT inhibitor, as described in [9], which is an agent for the inhibition of postprandial hypergiukaemia; [12] a human SGLT inhibitor as described in [9] above, which is an agent for the prevention or treatment of a disease associated with hypergiucemia; [1 3] a human SGLT inhibitor as described in [12] above, wherein the disease associated with hypergiukaemia is a disease selected from the group consisting of diabetes, glucose intolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricaemia and gout; [14] a human SG LT inhibitor as described in [9] above, which is an agent for inhibiting the progression of glucose intolerance in diabetes in a subject; [1 5] a pharmaceutical composition as described in [8] above, wherein the dosage form is a sustained release formulation; [1 6] a human SGLT inhibitor, as described in [9] above, wherein the dosage form is a sustained release formulation; [1 7] a method for the inhibition of postprandial hypergiukaemia, which comprises administering an effective amount of a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof; [1 8] a method for the prevention or treatment of a disease associated with hypergiukaemia, wherein the method comprises administering an effective amount of a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof; [19] a method for prevention or treatment as described in [1 8] above, wherein the disease associated with hypergiukaemia is a disease selected from the group consisting of diabetes, glucose intolerance, diabetic complications, obesity , hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia and gout; [20] a method for inhibiting the advance of glucose intolerance in subjects with diabetes, wherein the method comprises administering an effective amount of a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof; [21] the use of a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof for the manufacture of a pharmaceutical composition for the inhibition of postprandial hypergiucemia; [22] a use of a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with hyperglycemia; [23] an use as described in [22] above, wherein the disease associated with hyperglycemia is a disease selected from the group consisting of diabetes, glucose intolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia , hypercholesterolemia, hypertriglyceridemia, lipid metabolism disease, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia and gout; [24] the use of a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof for the manufacture of a pharmaceutical composition for the inhibition of the advance of glucose intolerance in a subject with diabetes; [25] a pharmaceutical composition as described in [8] above, which comprises the combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an IV inhibitor of dipeptidyl peptidase, an inhibitor phosphatase-1 B protein tyrosine, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a peptide-1 analog type glucagon, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product formation, a protein kinase inhibitor C, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, an N F-kB inhibitor of transcription factor, a lipid protease inhibitor, an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, an analogue of platelet-derived growth factor, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin , EGB-761, bimoclomol, sulodexide, Y-1 28, an antidiarrheal, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor , probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor , a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, a cholesterol ester transferase protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin conversion enzyme inhibitor, an antagonist of endothelin receptor, a diuretic agent, a calcium antagonist, an antihypertensive agent of vasodilatation, a sympathetic blocking agent, a centrally acting antihypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, an uricosuric agent and a urinary alkalizer; [26] a human SG LT inhibitor as described in [9] above, which comprises the combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose uptake inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a peptidase IV inhibitor of dipeptidyl, a phosphatase-1 B inhibitor of protein tyrosine, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-Quiroinsitol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin , an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product inhibition, a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a channel agonist of sodium, an N F-kB inhibitor of transcription factor, a lipid protease inhibitor, a dipeptidase-acid inhibitor linked by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analog, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine , 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrhoeal, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyltransferase inhibitor of acyl-coenzyme A cholesterol, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, an acid cotransporter inhibitor, sodium / biliary, an inhibitor of cholesterol ester transferase protein, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an enzyme-converting enzyme inhibitor, endothelin, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, an inhibitor of synthesis of uric acid, a uricosuric agent and a urinary alkalizer; [27] a method for the inhibition of postprandial hyperglycemia as described in [1 7] above, which comprises administering in combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, an inhibitor of glucose absorption, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, an inhibitor of hepatic gluconeogenesis, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 gonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product formation, a protein C kinase inhibitor, a receptor antagonist α-aminobutyric acid, a sodium channel agonist, an N F-kB inhibitor of transcription factor, a lipid protease inhibitor, an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor , a growth factor derived from platelets, an analogue of platelet-derived growth factor, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-1 28, an antidiarrheal, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor , a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a derivative of nicotinic acid, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, an inhibitor of cholesterol ester transferase protein , an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin conversion enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, an calcium antagonist, a vasodilation antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, an uricosuric agent and a urinary alkalizer; [28] a method for the prevention or treatment of disease associated with hypergiucemia as described in [1 8] above, which comprises administering in combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide , an insulin secretion enhancer, an SG LT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an IV inhibitor of peptidase dipeptidyl, a protein tyrosine-1B phosphatase inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, an inhibitor of hepatic gluconeogenesis, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, a amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product inhibitors, a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist , an N F-kB inhibitor of transcription factor, a lipid protease inhibitor, an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, an analogue of platelet-derived growth factor, epidermal growth factor, nerve growth factor, a derivative of carnitine, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrhoeal, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, a acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, an inhibitor of palmitoyl transferase of carnitine, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, a protein inhibitor of cholesterol ester transferase, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an antagonist of angiotensin II receptor, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, a sympathetic blocking agent, an anti-hypertensive agent of action central, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, an uricosuric agent and a urinary alkalizer; [29] a method for the inhibition of progression of glucose intolerance in subjects with diabetes as described in [19] above, which comprises administration in combination with minus one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a receptor antagonist, glucagon, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an IV inhibitor of dipeptidyl peptidase, a protein tyrosine phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose-inhibitor 6-phosphatase, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a peptide analogue -1 type glucagon, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, a formation inhibitor of advanced glycation end products, a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, a N F-kB inhibitor of transcription factor, a lipid protease inhibitor, a inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analog, epidermal growth factor, nerve growth factor, a derivative of carnitine, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartic, an inhibitor of Coenzyme A reductase of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor , a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a sequestrant of bile acid, a sodium / bile acid cotransporter inhibitor, an inhibitor of cholesterol ester transferase protein, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin conversion enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, an calcium antagonist, a vasodilation antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, an uricosuric agent and a urinary alkalizer; [30] A use of (A) or a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof and (B) at least a member selected from the group consisting of insulin sensitivity enhancer, an inhibitor of glucose absorption, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, an inhibitor of hepatic gluconeogenesis, Dq uiroinsitol, an inhibitor of glycogen synthase kinase-3, a glucagon-like peptide-1, a glucagon-like peptide-1 analog, a glucagon-like peptide-1 agonist, amylin, an amylin analog, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product formation, a protein C kinase inhibitor, a receptor antagonist acid -aminobutyric acid, a sodium channel agonist, an NF-kB inhibitor of transcription factor, a lipid protease inhibitor, an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a growth factor derived from platelets, an analog of platelet-derived growth factor, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartic, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, a acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, an inhibitor of palmitoyl transferase of carnitine, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, a protein inhibitor of cholesterol ester transferase, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist , a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, an agent of sympathetic blockade, a centrally acting anti-hypertension agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkanilizer, for the manufacture of a pharmaceutical composition for the inhibition of hyperglycemia postprandial; [31] A use of (A) or a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof and (B) at least a member selected from the group consisting of insulin sensitivity enhancer, an inhibitor of glucose absorption, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, an inhibitor of hepatic gluconeogenesis, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose uctase network inhibitor, an inhibitor of advanced gliding end-products, a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, an NF-kB inhibitor of transcription factor, a lipid protease inhibitor, an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a growth factor platelet-derived, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y- 1 28, an antidiarrheal, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, a acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a palmitoyl transferase inhibitor of carnitine, an inhibitor of squalene synthase, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, an inhibitor of cholesterol ester transferase protein, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, a receptor antagonist of endothelin, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, an ag sympathetic blocking agent, a centrally acting anti-hypertension agent, an a2-ad renoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkanilizer, for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with heperglycemia; [32] A use of (A) or a fused heterocyclic derivative as described in any of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a prodrug thereof and (B) at least a member selected from the group who consists of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analog, a glucagon receptor antagonist, a receptor kinase stimulant, insulin, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a tyrosine protein phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose- bisphosphatase, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a peptide agonist -1 type glucagon, amylin, an analogue of amylin, an amylin agonist, an inhibitor of the aldose uctase network, an inhibitor for the formation of advanced glycation end products, or n C protein kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, an N F-kB inhibitor of transcription factor, a lipid protease inhibitor, a dipeptidase-linked acid inhibitor by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, an analogue of platelet-derived growth factor, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartic, a coenzyme A uctase inhibitor of coenzyme A hydroxy methylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, an inhibitor of microsomal triglyceride transfer protein, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium / biliary acid cotransporter inhibitor, an inhibitor of cholesterol ester transferase protein, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin conversion enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, an sympathetic block, a centrally acting anti-hypertension agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkanilizer, for the manufacture of a pharmaceutical composition for inhibiting the advancement of glucose intolerance in patients with diabetes; and similar. In the present invention, the term "d6 alkyl group" means a branched straight chain alkyl group having from 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a propyl group, a isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a ter-pentyl group, a hexyl group or similar; the term "d-6 alkylene group" or "-C1-6 alkylene-" means a branched straight-chain alkylene group having 1 to 6 carbon atoms, such as a methylene group, an ethylene group, a trimethylene group , a tetramethylene group, a propylene group, a 1, 1 -dimethylethylene group or the like; and the term "C 1-4 alkylene group" or "C -C 4 alkylene-" means a branched straight-chain alkylene group having from 1 to 4 carbon atoms, such as a methylene group, an ethylene group, a group trimethylene, a tetramethylene group, a propylene group, a 1, 1 -dimethylethylene group or the like. The term "(C 1-6 alkyl) hydroxy group" means the group C 1-6 alkyl substituted by a hydroxy group; the term "dihydroxy group (d-6 alkyl)" means the group C1-6 above alkyl substituted by two hydroxy groups such as a 2,3-dihydroxypropyl group, a 1,3-dihydroxy-2-propyl group or the like; the term "amino group (C? _6 alkyl)" means the group C1_6 alkyl substituted by an amino group such as an aminomethyl group, a 2-aminomethyl group or the like; the term "carbamoyl (d-6 alkyl)" means the group C? _6 above alkyl substituted by a carbamoyl group; and the term "carboxy group (d-6 alkyl)" means the group C-6 above alkyl substituted by a carboxy group. The term "d-6-alkoxy group" means a branched straight-chain alkoxy group having from 1 to 6 carbon atoms, such as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, a pentyloxy group, an isopentyloxy group, a neopentyloxy group, a ter-pentyloxy group, a hexyloxy group or the like; the term "(1-6C) alkoxy hydroxy group" means the above d-6 alkoxy group substituted by a hydroxy group; the term "carboxy group (C? _6 alkoxy)" means a C1_6 alkoxy group substituted by a carboxy group; the term "carbamoyl group (d-6 alkoxy)" means the group C? -6-lower alkoxy substituted by a carbamoyl group; and the term "amino group (C-? 6 alkoxy)" means the group d-6-lower alkoxy substituted by an amino group. The term "C 1-6 alkylthio group" means a branched straight chain alkylthio group having from 1 to 6 carbon atoms, such as a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group, a group isobutylthio, a sec-butylthio group, a tert-butylthio group, a pentthylthio group, an isopentylthio group, a neopentylthio group, a tert-pentthylthio group, a hexylthio group or the like; the term "hydroxy group (d-6 alkylthio)" means the group C -6 above alkylthio substituted by a hydroxy group; the term "carboxyl group C1 -6 alkylthio)" means the group C1-6 alkylthio substituted by a carboxy group; and the term "amino group (d-β alkylthio)", means the group C1 -6 above alkylthio substituted by an amino group. The term "C2-6 alkenyl group" means a branched straight chain alkenyl group having from 2 to 6 carbon atoms, such as a vinyl group, an allyl group, a 1-propenyl group, a group isopropenyl, a 1-butenyl group, a 2-butenyl group, a 2-methylallyl group or the like; the term "C2-6 alkenylene group" or "-C2-6 alkenylene-" means a straight or branched chain alkenylene group having from 2 to 6 carbon atoms, such as a vinylene group, a propenylene group or the like; the term "C2-alkenylene group" means a straight or branched chain alkenylene group having from 2 to 4 carbon atoms such as a vinylene group, a propenylene group or the like; the term "(C2-6 alkenyl) hydroxy group" means a C2-6 alkenyl group substituted by a hydroxy group; the term "carboxy group (C 2-6 alkenyl)" means the C 2-6 alkenyl group substituted by a carboxy group; the term "cyano (C2-β-alkenyl) group" above substituted by a cyano group; the term "C2-6 alkenyloxy group" means a branched straight-chain alkenyl group having from 2 to 6 carbon atoms, such as a vinyloxy group, an allyloxy group, a 1-propenyloxy group, an isopropenyloxy group, a 1-butenyloxy group, a 2-butenyloxy group, a 2-methylalyloxy group or the like; the term "C2-6 alkenylthio group" means a straight or branched chain alkenylthio group having from 2 to 6 carbon atoms such as a vinylthio group, an allylthio group, a 1 -propenylthio group, an isopropenylthio group, a group 1-buthenylthio, a 2-butenylthio group, a 2-methylalylthio group or the like; the term "C2-6 alkynyl group" means a straight or branched chain alkynyl group having from 2 to 6 carbon atoms such as an ethynyl group, a 2-propynyl group or the like; and the term "C2-alkynylene group-" means a group straight or branched chain alkynylene having from 2 to 4 carbon atoms, such as an ethynylene group, a propynylene group or the like. The term "mono- or di- (C 1-6 alkyl) amino" group means a mono-substituted group through the group C1-6 alkyl or disubstituted alkyl through the same or different d-6 alkyl groups, such as defined earlier; the term "mono- or di- (C 1-6 alkyl) amino (d-6 alkyl)" group means the d-6-lower alkyl group substituted by the above mono- or di (C 1-6 alkyl) amino group; the term "mono- or di (d-6-alkyl) amino (d-6-alkoxy)" group means the above-substituted d-6 alkoxy group through the above mono- or di (d-6-alkyl) amino group; the term "mono or di [hydroxy (C1-C6 alkyl)] amino group" means an amino group substituted by the hydroxy (d-6 alkyl) group above or di substituted by any of the hydroxy groups (C? - 6 alkyl) above; the term "mono- or di- (C-? - 6 alkyl) ureido" group means a mono-substituted group of the C1-6 alkyl group or di-substituted by any of the above C1-C6 alkyl groups; the term "mono or di [hydroxy (d-6 alkyl)] ureido" group means a mono-substituted ureido group through the above hydroxy (d-6-alkyl) group or di-substituted through any of the hydroxy d- groups 6 alkyl) above; the term "mono- or di- (C 1-6 alkyl) sulfamide group" means a mono-substituted sulfamide group through the group d_6 alkyl or di-substituted through any of the above d-β alkyl groups; the term "mono or di group [hydroxy (C-? -6-alkyl)] sulfonamide "means a mono-substituted sulfamide group through the above hydroxy (C1-C6-alkyl) group or di-substituted through any of the hydroxy (C1-C6 alkyl) groups above the term "C2-7 acyl group" means a straight or branched chain acyl group having from 2 to 7 carbon atoms, such as an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a group valeryl, a pivaloyl group, a hexanoyl group or the like, the term "C2-7 acylamino group" means a substituted amino group through the C2-acyl group above, and the term "amino group (C2-7 acylamino)" means the C 2 -acrylamino group substituted by an amino group, such as a 2-aminoacetylamino group, a 3-aminopropionylamino group or the like The term "C 1-6 alkylsulfonyl group" means a chain alkyl sulfinyl group straight or branched that has 1 to 6 carbon atoms, such as a group I thiisulfonyl, an ethylsulfonyl group or the like; the term "C 1-6 alkylsulfonyl group" means a straight or branched chain alkyl sulfonyl group having from 1 to 6 carbon atoms, such as a methanesulfonyl group, an ethanesulfonyl group or the like; the term "C1 -6 alkyl-sulfonylamino group" means an amino group substituted by the above group d-6 alkylsulfonyl; the term "carbamoyl group (d-6 alkyl-sulfonylamino)" means the group C1 -6 alkylsulfonylamino above its substituted by a carbamoyl group, such as a carbamoylmethanesulfonylamino group or the like; and the term "C1 -6 alkylsulfonylamino (d-6 alkyl) group" means the C -6 alkyl group previous replaced by the group d-6 alkylsulfonylamino above. The term "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom; the term "halo (d-6 alkyl) group" means the group C? -6 substituted lower alkyl through any of 1 to 3 halogen atoms as defined above; the term "halo group (C? -6 alkoxy)" means the above d-6 alkoxy group its substituted by any of 1 to 3 halogen atoms as defined above; and the term "halo (d-6 alkylthio) group" means the group d.6 above substituted alkylthio through any of 1 to 3 halogen atoms as defined above. The term "C2-7 alkoxycarbonyl group" means a straight or branched chain alkoxycarbonyl group having from 2 to 7 carbon atoms, such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, an isobutyloxycarbonyl group, a sec-butoxycarbonyl group, a tert-butoxycarbonyl group, a pentyloxycarbonyl group, an isopentyloxycarbonyl group, an neopentyloxycarbonyl group, a tert-pentyloxycarbonyl group, a hexyloxycarbonyl group or the like; the term "C2-7 alkoxycarbonyl (d-6 alkyl) group" means the above d-6 alkoxy group substituted by the above C2-7 alkoxycarbonyl group; the term "C2-alkoxycarbonyl (C1-6 alkoxy)" means the group C1-6 alkoxy above substituted by the group C2-7 alkoxycarbonyl above; the term "C2-7 alkoxycarbonyl (C1-6 alkylthio) group" means the group C-? -6-lower alkylthio substituted by the C2-7 alkoxycarbonyl group previous; and the term "C2-7 alkoxycarbonyl (C2.6 alkenyl)" group means the C2-6 alkenyl group substituted by the above C2-7 alkoxycarbonyl group. The term "C3-7 cycloalkyl group" or "C3-7 cycloalkyl group" means a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group or a cycloheptyl group; the term "C3-7 cycloalkyloxy group" means a hydroxy group substituted by the above cycloalkyl group C3-7; the term "C3-7 cycloalkyl (d6 alkyl) group" means the above d-6 alkyl group substituted by the C3-7 cycloalkyl group above; the term "C 3-7 cycloalkyl (C 1-6 alkoxy)" means the group C 1-6 above alkoxy substituted by the group C 3-7 cycloalkyl above; and the term "C3-7 cycloalkyl (C1-6 alkylthio) group" means the group C6-alkylthio above substituted by the group C3-7 cycloalkyl above. The term "heterocycloalkyl group" or "heterocycloalkyl-" means a 3 to 7-membered aliphatic heterocyclic group containing any of 1 or 2 heteroatoms other than the selected bond position of an oxygen atom, a sulfur atom and a hydrogen atom. nitrogen in the ring, which is derived from morpholine, thiomorpholine, tetrahydrofuran, tetrahydropyran, aziridine, azetidine, pyrrolidine, imidazolidine, oxazoline, piperidine, piperazine, pyrazolidine, pyrroline, imidazoline or the like, or a 5- or 6-membered aliphatic heterocyclic group fused with a 6-membered ring containing any of 1 or 2 heteroatoms other than the selected bond position of an oxygen atom, a sulfur atom and a nitrogen atom in the ring, which is derived from indoline, isoindoline, tetrahydroindoline, tetrahydroisoindoline, hexahydroindoline, hexahydroisoindoline or the like. The term "heterocycloalkyl (C 1-6 alkyl) group" means the group C1-6 above alkyl substituted by the above heterocycloalkyl group; the term "heterocycloalkyl (C 1-6 alkoxy)" means the group C 1-6 above alkoxy substituted by the above heterocycloalkyl group; and the term "heterocycloalkyl group (C 1-6 alkylthio)" means the above d-6 alkylthio group substituted by the above heterocycloalkyl group. The term "C6-? Or aryl group" or "C6-? Or aryl-" means an aromatic cyclic hydrocarbon group having 6 or 10 carbon atoms, such as a phenyl group, a naphthyl group or the like; the term "C6-? or aryl (C1-6 alkyl) group" means the group d-6 above alkyl substituted by the group C6-? or previous aryl; the term "C6-10 aryl (d-6 alkoxy)" means the above d-6 alkoxy group substituted by the C6-? or aryl group above; and the term "C6-? or aryl (C1-6 alkylthio)" group means the above d-6 alkylthio group substituted by the C6-? or aryl group above. The term "C6-? Or arylsulfonylamino group" means a sulfonylamino group having the C6-? Or aryl group above, such as a benzenesulfonylamino group or the like; the term "C6-? or aryl (C2-7 alkoxycarbonyl) group" means the above C2-alkoxycarbonyl group substituted by the C6-? or aryl group above; and the term "heteroaryl group" or "heteroaryl-" means a 5- or 6-membered aromatic heterocyclic group containing from 1 to 4 different heteroatoms at the selected bond position of a oxygen atom, a sulfur atom and a nitrogen atom in the ring, which is derived from thiazole, oxazole, isothiazole, isoxazole, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, thiophene, imidazole, pyrazole, oxadiazole, thiodiazole, tetrazole, furazan or the like, or a 5- or 6-membered aromatic heterocyclic group fused with a 6-membered aromatic ring containing from 1 to 4 hetero atoms different from the linked bond position of an oxygen atom, a sulfur atom and a nitrogen atom in the ring, which is derived from Nature, isoindole, benzofuran, isobenzofuran, benzotriofen, benzooxazole, benzothiazole, indazole, benzoimidazole, quinoline, isoquinoline, phthalazine, quinoxaline, quinazoline, cinnoline, indolizine, naphthyridine, pteridine or the like . The term "heteroaryl group (C 1-6 alkyl)" means the group C1-6 above alkyl substituted by the above heteroaryl group; the term "heteroaryl group (C? -6 alkoxy)" means the group C1-6 alkoxy above substituted by the above heteroaryl group; and the term "heteroaryl group (C-? - 6 alkylthio)" means the group C1-6 alkylthio above substituted by the above heteroaryl group. The term "aliphatic cyclic amino group" means a 5- or 6-membered aliphatic cyclic amino group which may contain a hetero atom different from the nitrogen atom at the selected bond position of an oxygen atom, a sulfur atom and an atom of nitrogen in the ring, such as a morpholino group, a thiomorpholino group, a 1-aziridinyl group, a 1-azetidinyl group, a 1-pyrrolidinyl group, a piperidino group, a 1-imidazolidinyl group, a 1-piperazinyl group, a pyrazolidinyl group or the like; the term "aromatic cyclic amino group" means a 5-membered aromatic cyclic amino group which may contain from 1 to 3 nitrogen atoms in the ring other than the nitrogen atom in the linking position, such as a 1-imidazolyl group, a 1-pyrrolyl group, a pyrazolyl group, a 1-tetrazolyl group or the like; the term "aromatic cyclic amino group (C 1-6 alkyl)" means the group d-6 above alkyl substituted by the above cyclic aromatic amino group; the term "(C1-C6 alkoxy) aromatic cyclic amino group" means the d-6 alkoxy group substituted by the above cyclic aromatic amino group; and the term "aromatic cyclic amino group (d-6 alkylthio)" means the group C-6 above alkylthio substituted by the above cyclic aromatic amino group. The term "hydroxy-protective group" means a protective hydroxy group used in organic synthesis in general such as a methyl group, benzyl group, methoxymethyl group, an acetyl group, a pivaloyl group, a benzoyl group, a tert-butyldimethylsilyl group, a tert-butyldiphenylsilyl group, an allyl group or the like; the term "amino-protecting group" means a protective-amino group used in organic synthesis in general such as a benzyloxycarbonyl group, a tert-butoxycarbonyl group, a benzyl group, an acetyl group, a trifluoroacetyl group or the like; and the term "protecting group-carboxy" means a protective-carboxy group used in organic synthesis in general, such as a methyl group, an ethyl group, a benzyl group, a butyldimethylsilyl group, an allyl group or the like.

In addition, in the substituent Q, the link on the left side means a link to a fused ring containing nitrogen, and the link on the right side means a link to a ring A. The compounds represented by the above general formula (I) of the present invention, can be prepared according to the following analogous procedures or procedures thereof, or other procedures described in the literature or analogous procedures thereof.

In the formula, E 1 a represents a hydrogen atom, a fluorine atom or a benzyloxy group; E2a represents a hydrogen atom, a fluorine atom, a methyl group or a benzyloxymethyl group; L1 represents a hydrogen atom, a chlorine atom, a bromine atom or an iodine atom; M represents a benzyl group; G1 represents a group represented by a formula: or a formula: wherein M, E1 a and E2a have the same meanings as described above; G2 represents the previous G with a hydroxy group protected by a benzyl group; R1 to R4, A1, A2 and G have the same meaning as defined above, and provided that in the case where there is a hydroxy group, an amino group and / or a carboxy group in each compound, a compound having a group Protector can be used properly. Process 1 A compound represented by the general formula (III) above, can be prepared by subjecting a compound represented by the general formula (ll) above to lithiation using a lithiation reagent such as n-butyllithium, sec-butyllithium, tert-butyllithium, lithium diisopropylamide or the like in an inert solvent. As the solvent used, it can be illustrated, for example, tetrahydrofuran, diethyl ether, a mixed solvent thereof and the like. The Reaction temperature is usually from -100 ° C to room temperature, and the reaction time is usually from 1 minute to 3 hours, varying based on a starting material, solvent or reaction temperature used. Process 2 A compound represented by the general formula (IV) above, can be prepared by subjecting a compound represented by the general formula (III) above to condensation with a sugar lactone represented by the general formula (Ga) or (Gb) above in an inert solvent. As the solvent used, for example, tetrahydrofuran, diethyl ether, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from -100 ° C to room temperature, and the reaction time is usually from 5 minutes to 5 hours, varying based on a starting material, solvent or reaction temperature used. Process 3 A compound represented by the general formula (V) above, can be prepared by subjecting a compound represented by the general formula (IV) above to reduction to remove a hydroxy group for the other anomer position using a reagent such as triethylsilane, trisopropylsilane or the like in the presence of a complex of boron trifluoride-diethyl ether in an inert solvent. As the solvent used, it can be illustrated, for example, acetonitrile, dichloromethane, 1,2-dichloroethane and a mixed solvent of the same and similar. The reaction temperature is usually from -20 ° C to room temperature, and the reaction time is usually from 30 minutes to 1 day, with variation based on a starting material, solvent and reaction temperature used. Process 4 A compound represented by the above general formula (I) of the present invention can be prepared by subjecting a compound represented by the general formula (V) above: 1) to catalytic hydrogenation using a palladium catalyst, such as a powder of palladium-carbon or the like in an inert solvent, or 2) to treatment using a reagent such as ethanethiol in the presence of an acid such as boron trifluoride-diethyl ether complex to remove the benzyl group in an inert solvent. As the solvent used in the catalytic hydrogenation, for example, methanol, ethanol, ethyl acetate, tetrahydrofuran, acetic acid, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0 ° C to reflux temperature, and the reaction time is usually from 1 hour to 2 days, with variation based on a starting material, solvent and reaction temperature used. As the solvent used in the acid treatment, it is possible to sample, for example, dichloromethane, 1,2-dichloroethane, acetonitrile, a mixed solvent thereof and the like. The temperature is usually from 0 ° C to reflux temperature, and the reaction time normally it is from 30 minutes to 1 day, with variation based on a starting material, solvent and reaction temperature used. The starting materials used in the above manufacturing methods can be prepared according to the methods described in the literatures or analogous processes thereof. In addition, of the compounds represented by the above general formula (II), a compound represented by the general formula (1 a), (11 b) or (1) which is found in accordance with Processes 5 can also be prepared to 9.

In the formula, one of L2 and L3 represents a hydrogen atom, a chlorine atom, a bromine atom or an iodine atom; and the other represents a hydrogen atom, an atom of halogen, a C1_6 alkyl group, a halo (C_6 alkyl) group, a hydroxy (d_6 alkyl) group, a dihydroxy group (C_6 alkyl), a C1_6 alkoxy group, a C2 group -7 alkoxycarbonyl (d-6 alkyl), a carboxy group (d-6 alkoxy), a C 3-7 cycloalkyl group or a C 3-7 cycloalkyl (C 1-6 alkyl) group; L4 represents -P (= O) (OR °) 2 or -P + (PPh3) 3X ", R ° represents a C1 -6 alkyl group, Ph represents a phenyl group, X represents a chlorine atom, a bromine atom or an iodine atom, one of R10 and R1 represent a group represented by the general formula: , and the other represents a hydrogen atom, a halogen atom, a d-6 alkyl group, a halo (C 1-6 alkyl) group, a hydroxy (C -? - 6 alkyl) group, a dihydroxy group (C 1 - 6 alkyl), a d.6 alkoxy group, a C2-7 alkoxycarbonyl group (d-6 alkyl), a carboxy group (C1-6 alkyl), a C3-7 cycloalkyl group or a C3-7 group. (C 1-6 alkyl) cycloalkyl; one of R12 and R3 represents a group represented by the general formula: , and the other represents a hydrogen atom, a halogen atom, a d-6 alkyl group, a halo (C 1-6 alkyl) group, a hydroxy group (C? -6 alkyl), a dihydroxy group (C 1-6) alkyl), a C1 -6 alkoxy group, a C 2-7 alkoxycarbonyl (C 1-6 alkyl) group, a carboxy (C 1-6 alkyl) group, a C 3-7 cycloalkyl group or a C 3-7 cycloalkyl (C 1-6 alkyl) group; one of R14 and R15 represents a formyl group, and the other represents a hydrogen atom, a halogen atom, a C1.6 alkyl group, a halo (C1-6 alkyl) group, a hydroxy (C1-6 alkyl) group , a dihydroxy (C 1-6 alkyl) group, a d-6 alkoxy group, a C 2-7 alkoxycarbonyl group (C-6 alkyl), a carboxy (C 1-6 alkyl) group, a C 3-7 cycloalkyl group or a group C3-7 cycloalkyl (C -? - 6 alkyl); one of R16 and R17 represents a group represented by the general formula: , and the other represents a hydrogen atom, a halogen atom, a d-6 alkyl group, a halo (d-6 alkyl) group, a hydroxy group (d-6 alkyl), a dihydroxy group (C 1-6 alkyl), a d-6 alkoxy group, a C 2-7 alkoxycarbonyl group (d 6 alkyl), a carboxy group (C 1-6 alkyl), a C 3-7 group cycloalkyl or a C 3-7 cycloalkyl (C 1-6 alkyl) group; Q1 represents a vinyl group or an ethynyl group; Q2 represents a single bond, -C1 -4 alkenylene-, -C2-4 alkynylene-, -C C? Alalkylene-O-, -C1-4 alkylene-S-, -C?? -4alkylene-O- C1 -6 alkylene-or-C-4-alkylene-SC-? 6-alkylene-; Q3 represents a vinylene group or an ethynylene group; and R2, R3, R5, R6, A1, A2 and ring A have the same meanings as defined above.

Process 5 A compound represented by the general formula (Ha) above can be prepared by subjecting a compound represented by the above general formula (VI) to Heck reaction or Sonogashira reaction with a compound represented by the general formula (Vi l) above using a catalyst of palladium, such as a palladium and a carbon powder, palladium acetate, tetrakis (triphenylphosphine) palladium, dibenzylidene acetone palladium, bis (triphenylphosphine) -palladium dichloride in the presence or absence of a ligand such as tris (2-methylphenyl) ) phosphine, triphenylphosphine or the like in the presence of a base such as triethylamine, N, N-diisopropylethylamine, sodium tert-butoxide, potassium tert-butoxide, sodium carbonate, potassium carbonate, cesium fluoride or the like and in the presence or absence of copper iodide (I) in an inert solvent. As the solvent used, it is possible to use, for example, acetonitrile, toluene, tetrahydrofuran, triethylamine, N, N-diisopropylethylamine, a solvent and mixing thereof and the like. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, with variation based on a starting material, solvent and reaction temperature used. Process 6 A compound represented by the general formula (I lb) above, can be prepared by subjecting a compound represented by the general formula (I a) above: 1) to catalytic hydrogenation using a palladium catalyst, such as a palladium-carbon powder or an inert solvent, or 2) a reduction of diimide in the presence or absence of a base such as triethylamine, N, N-diisopropylethylamine or the like using a reagent such as 2-, 4,6-triisopropylbenzenesulfonyl hydrazide or the like in an inert solvent. As the solvent used in the catalytic hydrogenation, for example, methanol, ethanol, ethyl acetate, tetrahydrofuran, acetic acid, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from 0 ° C to reflux temperature, and the reaction time is usually from 1 hour to 2 days, with variation based on a starting material, solvent and reaction temperature used. As the solvent used in the reduction of diimide, it can be illustrated, for example, tetrahydrofuran, diethyl ether, a mixed solvent thereof and the like. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 3 days, with variation based on a starting material, solvent and reaction temperature used. Process J A compound represented by the general formula (VI II) above can be prepared by subjecting a compound represented by the above general formula (VI), 1) to lithiation in the presence or absence of an additive such as N, N, N ' , N'-tetramerylethylenodine, hexamethylphosphoramide or the like using a base such as n- butyllithium, sec-butyllithium, tert-butyllithium or the like in an inert solvent or preparation of a Grignard reagent in the presence of an additive such as iodine, 1,2-dibromoethane or similar using magnesium in an inert solvent, and subsequently 2) to formylation using N. N-dimethylformamide. As the solvent used, it can be illustrated, for example, tetrahydrofuran, diethyl ether, a mixed solvent thereof and the like. The reaction temperature is usually from -100 ° C to reflux temperature in reaction 1) and is usually from -100 ° C to room temperature in reaction 2), and the reaction time is usually from 1 minute to 1 hour in reaction 1), and usually from 30 minutes to 1 day in reaction 2), with variation based on a starting material, solvent and reaction temperature used. Process 8 A compound represented by the general formula (Ie) above prepared by subjecting a compound represented by the general formula (VI II) above to the Wittig reaction or Horner-Emmons reaction in the presence of a base such as the hydride of sodium, sodium hydroxide, potassium tert-butoxide, N-butyllithium, tert-butylidene or the like using a compound represented by the general formula (IX) above in an inert solvent. As the solvent used in the reaction, there can be illustrated, for example, tetrahydrofuran, N, N-dimethylformamide, dimethyl sulfoxide, methanol, ethanol, acetonitrile, water and a mixed solvent thereof and the like. The temperature is usually from 0 ° C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, with variation based on a stag material, solvent and reaction temperature used. Process 9 A compound represented by the general formula (I IB9 above) can be prepared by subjecting a compound represented by the general formula (Ie) above, 1) to catalytic hydrogenation using a palladium catalyst, such as palladium-carbon powder or similar in an inert solvent, or 2) to diimide reduction in the presence or absence of a base such as triethylamine, N. N-diisopropylethylamine or the like using a reagent such as 2,4,6-triisopropyl-benzenesulfonylhydrazide or the like in an inert solvent. As the solvent used in the catalytic hydrogenation, it can be illustrated, for example, methanol, ethanol, ethyl acetate, tetrahydrofuran, acetic acid, a mixed solvent thereof or the like. The temperature is usually from 0 ° C to reflux temperature, and the reaction time is usually from 1 hour to 2 days, with variation based on a stag material, solvent and reaction temperature used. As the solvent used in the reduction of diimide, there may be illustrated, for example, tetrahydrofuran, diethyl ether, a mixed solvent thereof and the like. The temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 3 days, with variation based on a stag material, solvent and reaction temperature used. Of the compounds represented by the general formula (I I) above, a compound in which A1 is a sulfur atom can also be prepared; A2 is a carbon atom, and L is a hydrogen atom, according to the following processes from 1 0 to 1 1 or from 12 to 1 5.

In the formula, L5 represents a chlorine atom, a bromine atom, and an iodine atom; R represents a methyl group or a group ethyl, or both R are linked together to form an ethylene group or a trimethylene group; R18 represents a methyl group or an ethyl group; and R1 to R4 have the same meanings as described above. Process 10 A compound represented by the general formula (Xl l) above can be prepared by subjecting a compound represented by the general formula (X) to S-alkylation in the presence of a base such as potassium carbonate, cesium carbonate, triethylamine , N, N-diisopropylethylamine or the like, using a compound represented by the general formula (XI) in an inert solvent. As the solvent used, it can be illustrated, for example, N, N-dimethylformamide, acetone, dichloromethane, a mixed solvent thereof or the like. The reaction temperature is usually from 0 ° C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, with variation based on a stag material, solvent and reaction temperature used. Process 1 1 A benzothiophene derivative represented by the general formula (I id) above can be prepared by subjecting a compound represented by the general formula (Xll) above to cyclization in the presence of a phosphoric acid in an inert solvent. As the solvent used, benzene, chlorobenzene, toluene and the like can be used, for example. The temperature is usually from room temperature to reflux temperature, and the Reaction time is usually from 1 hour to 1 day, with variation based on a stag material, solvent and reaction temperature used. Process 1 2 A compound represented by the general formula (XIV) can be prepared by subjecting a compound represented by the above general formula (Xl ll), 1) to lithiation in the presence or absence of an additive such as N, N, N ', N'-tetramethylethylenediamine, hexamethylphosphoramide or the like, using a base such as n-butyllithium, sec-butyl-lithium, tert-butyl lithium, lithium diisopropylamine or the like in an inert solvent, and subsequently, 2) to formylation using N, N-dimethylformamide. As the solvent used, it can be illustrated, for example, tetrahydrofuran, diethyl ether, a mixed solvent thereof and the like. The reaction temperature is usually from -1 00 ° C to 0 ° C in the reaction, 1) and usually from -1 00 ° C to room temperature in reaction 2), and the reaction time is usually from 30 minutes up to 5 hours in reaction 1), and usually from 30 minutes to 1 day in reaction 2), with variation based on the starting material, solvent and reaction temperature used. Process 1 3 A benzothiophene derivative represented by the above general formula (XVI) can be prepared by subjecting a compound represented by the above general formula (XIV) to cyclization in the presence of a base such as triethylamine, N, N-diisopropylethylamine, potassium carbonate, cesium carbonate, potassium tert-butoxide, sodium hydride or the like using a mercaptoacetic acid ester represented by the general formula (XV) in an inert solvent. As the solvent used, it can be illustrated, for example, N, N-dimethylformamide, dimethisulfoxide, tetrahydrofuran, methanol, ethanol, n-butanol and the like. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, with variation based on a starting material, solvent and reaction temperature used. Process 14 A carboxylic acid derivative represented by the general formula (XVII) above can be prepared by subjecting a compound represented by the above general formula (XVI) to hydrolysis in the presence of a basic substance such as sodium hydroxide, hydroxide potassium or similar. As the solvent used, it can be illustrated for example, methanol, ethanol, 2-propanol, tetrahydrofuran, water, a mixed solvent thereof and the like. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, with variation based on a starting material, solvent and reaction temperature used. Process 1 5 A compound represented by the formula can be prepared General (I id) above, subjecting a compound represented by the general formula (XVII) above to decarboxylation using a catalyst such as copper powder or the like in an inert solvent. As the solvent used, it can be used, for example, quinoline and the like can be used. The reaction temperature is usually from 1 00 ° C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, with variation based on a starting material, solvent or reaction temperature used. Of the compounds represented by the general formula (I 1) above, it can also be prepared according to the following processes from 1 6 to 1 8, a compound wherein L 1 is a hydrogen atom; one of R1 and R4 is a chlorine atom, a bromine atom or an iodine atom, and the other is a hydrogen atom, a halogen atom, a d-6 alkyl group, a halo (C1-6 alkyl) group ), a hydroxy group (C? -6 alkyl), a dihydroxy group (d-6 alkyl), a C? -6 alkoxy group, a C2-7 alkoxycarbonyl group (C? -6 alkyl), a carboxyl group (C 1-6 alkyl), a C 3 -cycloalkyl group, or a C 3-7 cycloalkyl (C 1-6 alkyl) group; and R9 is a C1-6 alkyl group; (He) (XX) In the formula, one of L4 and L5 represent a chlorine atom, a bromine atom or an iodine atom and the other represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo group (C ? -6 alkyl), a hydroxy (C 1-6 alkyl) group, a dihydroxy group (C? -6 alkyl), a C 1-6 alkoxy group, a C 2-7 alkoxycarbonyl group (C-6 alkyl), a carboxy group (C? -6 alkyl), a C3-7 cycloalkyl group, or a C3-7 cycloalkyl (d-6 alkyl) group; one of L6 and L7 represents MgCI, MgBr, or Mg l, and the other represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo (C1-6 alkyl) group, a hydroxy group (C ? -6 alkyl), a dihydroxy group (C-6 alkyl), a d-6 alkoxy group, a C 2-7 alkoxycarbonyl group (C 1-6 alkyl), a carboxy (C 1-6 alkyl) group, a C 3- group 7-cycloalkyl, or a C 3-7 cycloalkyl (C 1-6 alkyl) group; Q4 represents a single bond, -d-5 alkylene-, C2-5 alkylene-, C2-5 alkynylene-, C1.5 alkylene-O-, -C1-5 alkylene-S-, -C1-5 alkylene-OC- ? -6 alkylene-, -C 1 -5 alkylene-S-C 1-6 alkylene- or -C 1-5 alkylene-CON (R 6) -; one of R18 and R19 represents a group represented by a general formula: and the other represents a hydrogen atom, a halogen atom, a C? .e alkyl group, a halo (d-6 alkyl) group, a hydroxy group (C? -6 alkyl), a hydroxy group (d) .6 alkyl), a C1 -6 alkoxy group, a C2-7 alkoxycarbonyl group (C6-6 alkyl), a carboxy group (d-6 alkyl), a C3-7 cycloalkyl group or a C3-7 cycloalkyl group ( C? -6 alq uilo); one of R20 and R21 represent a group represented by a general formula: and the other represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halo (C6-6 alkyl) group, a hydroxy (C6-6 alkyl) group, a dihydroxy group (C1-6) 6 alkyl), a C 1-6 alkoxy group, a C 2-7 alkoxycarbonyl group (C 1-6 alkyl), a carboxy group (d-6 alkyl), a C 3-7 cycloalkyl group, or a C 3-7 cycloalkyl group (C -? _6alquilo); and a ring A, A1, A2, R2, R3, R5, R6, and R8 have the same meanings as defined above. Process 1 6 A Grignard reagent represented by the above general formula (XIX) can be prepared by allowing a compound represented by the general formula (XVII I) above to react with a magnesium metal in the presence of an activating agent, such as a catalytic amount of iodine or the like in an inert solvent. As the solvent used, for example, diethyl ether, tetrahydrofuran, a mixed solvent thereof and the like can be used. The reaction temperature is usually from 0 ° C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, with variation based on the starting material, solvent and reaction temperature used. Process 1 7 An alcohol derivative represented by the above general formula (XX) can be prepared by allowing a compound represented by the general formula (XXI) above to react with a Grignard reagent represented by the above general formula (XIX) in a solvent inert. As the solvent used, it can be illustrated, for example, diethyl ether, tetrahydrofuran, and the like. The reaction temperature is usually from -20 ° C to reflux temperature, and the reaction time is usually from 30 minutes to 1 day, with variation based on a starting material, solvent and reaction temperature used. Process 1 8 A benzothiophene derivative represented by the general formula (Ie) above can be prepared by subjecting an alcohol derivative represented by the general formula (XX) above to reduction in the presence of iodotrimethylsilane in an inert solvent. As the solvent used, acetonitrile and the like may be used for example. The reaction temperature is usually from -20 ° C to reflux temperature, and the reaction time is usually from 1 5 minutes to 1 day, with variation based on a starting material, solvent and reaction temperature used. Of the compounds represented by the general formula (I I) above, it is also possible to prepare a compound represented by the general formula (I) that follows, according to the following Process 1 9.

In the formula, one of R22 and R23 represent a group represented by the general formula: wherein Q5 represents -d-6 alkylene-; Q6 represents an oxygen atom, a sulfur atom, -O-C? -6alkyl-, or -S-C? -6 alkyl-; R5, R6, and ring A have the same meanings as defined above, and the other represents a hydrogen atom, a hydroxy group, an amino group, a halogen atom, a C1 -6 alkyl group, a C1 group- 6 alkoxy, a cyano group, a carboxy group, a C2-7 alkoxycarbonyl group, a carbamoyl group, a group mono or di (d_6 alkyl) amino, a halo (d-6 alkyl) group, a hydroxy group (C? -6 alkyl), a cyano group (d-6 alkyl), a carboxy group (C 1-6 alkyl) , a C 2-7 alkoxycarbonyl (C 1-6 alkyl), a carbamoyl (C 1-6 alkyl), a (C 1-6 alkylamino) amino group, a mono- or di (C 1-6 alkyl) amino group (d- 6 alkyl), a halo (C? -6 alkoxy), a hydroxy (C? -6 alkoxy), a carboxy (C1-6 alkoxy), a C2-7 alkoxycarbonyl (C? -6 alkoxy) group, a carbamoyl group (C 1-6 alkoxy), an amino group (C? -6 alkoxy), a mono- or di (C? -6 alkyl) amino group (C? -6 alkoxy), a C3-7 cycloalkyl group, a C3-7 cycloalkyloxy group, a C3-7 cycloalkyl (C1-6 alkyl) group, or a C3-7 cycloalkyl (C-? 6 alkoxy) group; one of R24 and R25 represent a group represented by a general formula: -Q5-L8 wherein L8 represents a chlorine atom, a bromine atom, an iodine atom, a mesyloxy group or a tosyloxy group; Q 5 has the same meaning as defined above, and the other represents a hydrogen atom, a hydroxy group, an amino group, a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group, a cyano group, a carboxy group, a C 2-7 alkoxycarbonyl group, a carbamoyl group, a mono- or di (C? -6 alkyl) amino group, a halo group (C 1-6 alkyl), a hydroxy group (C? -6 alkyl) , a cyano group (C-6 alkyl), a carboxy group (C 1-6 alkyl), a C 2-7 alkoxycarbonyl group (C? -6 alkyl), a carbamoyl group (C? -6 alkyl), an amino group (C? -6 alkyl), a mono or di (d-6 alkyl) amino group (C? .6 alkyl), a halo (C1-6 alkoxy) group, a hydroxy (C1-6 alkoxy) group, a carboxy group (C1 -6) alkoxy), a C 2-7 alkoxycarbonyl group (d 6 alkoxy), a carbamoyl group (C 1-6 alkoxy), an amino group (C 1-6 alkoxy), a mono- or di (C? -6 alkyl) amino group ( C1 -6 alkoxy), a C3-7 cycloalkyl group, a C3-7 cycloalkyloxy group, a C3-cycloalkyl group (C -6 alkyl), or a C3-7 cycloalkyl (C1-6 alkoxy) group; and A1, A2, R2, and R3 have the same meanings as defined above. Process 1 9 A compound represented by the general formula (I 1f) above can be prepared by subjecting a compound represented by the general formula (XXI) above to condensation with a compound represented by the general formula (XXI I) in the presence of a base such as sodium iodide, potassium hydroxide, potassium tert-butoxide, cesium carbonate or the like in an inert solvent. As the solvent used in the condensation reaction, there can be illustrated, for example, tetrahydrofuran, N, N-dimethylformamide, dimethyl sulfoxide, acetone, methanol and a mixed solvent thereof and the like. The reaction temperature is usually from 0 ° C to reflux temperature, and the reaction time is usually from 1 hour to 1 day, with variation based on a starting material, solvent and reaction temperature used.

In the case of compounds having a hydroxy group, an amino group and / or a carboxy group in the above processes, they can also be used in each reaction after introducing any protection group in the usual way as occasion requires. The protection group can be optionally removed in any subsequent reaction in the normal way. The compounds represented by the above general formula (I) of the present invention, obtained through the above production processes, can be isolated and purified through conventional separation means, such as fractional recrystallization, purification using chromatography, extraction of solvent and solid phase extraction. The fused heterocyclic derivatives represented by the general formula (I) above of the present invention can be converted into their pharmaceutically acceptable salts in the usual manner. Examples of such salts include acid addition salts are mineral acids, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid and the like, acid addition salts with organic acids such as formic acid, acetic acid, methanesulfonic acid, benzenesulfinic acid, p-toluenesulfonic acid, propionic acid, citric acid, succinic acid, tartaric acid, fumaric acid, butyric acid, oxalic acid, malonic acid, maleic acid, lactic acid, malic acid, carbonic acid, glutamic acid, aspartic acid and the like, salts with inorganic bases, such as sodium salt, potassium salt and the like, and salts with organic bases such as N-methyl-D-glucamide, N, N'-dibenzylethylenediamine, 2-aminoethanol , tris (hydroxymethyl) aminomethane, arginine, lysine and the like. The compounds represented by the general formula (I) above of the present invention include their solvates with pharmaceutically acceptable solvents, such as water and ethanol.

Of the fused heterocyclic derivatives represented by the general formula (I) above of the present invention and the prodrugs thereof, there are two geometric isomers, cis (Z) -isomer and trans (E) -isomer, in each compound having a unsaturated link In the present invention, any of the isomers may be employed. Of the fused heterocyclic derivatives represented by the general formula (I) above of the present invention and the prodrugs thereof, there are two optical isomers, R-isomer and S-isomer, in each compound having an asymmetric carbon atom excluding the sugar portion. In the present invention, any of the optical isomers can be employed, and a mixture of both optical isomers can also be employed. A prodrug of a compound represented by the above general formula (I) of the present invention can be prepared, introducing a suitable group to form a prodrug in any of one or more groups selected from a hydroxy group, an amino group and a cyclic amino group, such as a pyrazole ring, a piperazine ring or the like of the compound represented by the formula (I) above using a corresponding reagent to produce a prodrug such as a halide compound or the like in the usual manner, and subsequently isolating in a suitable manner and purifying in the usual manner as occasion requires. As a group to form a prodrug used in a hydroxy group or an amino group, for example, a C 2-7 acyl group, a C 1-6 alkoxy group (C 2-7 acyl), a C 2-7 alkoxycarbonyl group (C 2-7 acyl), a C 2-7 group can be illustrated. 7 alkoxycarbonyl, a C 1-6 aryl group (C 2-7 alkoxycarbonyl), a C 1-6 alkoxy group (C 2-7 alkoxycarbonyl), or the like. As a group to form a prodrug used in a cyclic amino group, for example, a C 2-7 acyl group, a C 1-6 alkoxy group (C 2-7 acyl), a C 2-7 alkoxycarbonyl group (C 2-7) can be used. acyl), a C2-7 alkoxycarbonyl group, a C6-? or aryl (C2-alkoxycarbonyl), a C -? - 6 (C2-7 alkoxycarbonyl) alkoxy group, a (C2-7 acyloxy) methy1 group, a 1- (C2-7 acyloxy) ethyl group, a group (C2- 7-alkoxycarbonyl) -oxymethyl, a 1 - [(C 2-7 alkoxycarbonyl) oxy] ethyl group, a (C 3-7 cycloalkyl) oxycarbonyloxymethyl group, a 1 - [(C 3-7 cycloalkyl) oxycarbonyl) ethyl group, or the like. The term "C 1-6 alkoxy group (C 2-7 acyl)" means the C 2-7 acyl group substituted by the above Ci-β alkoxy group; the term "C2-7 alkoxycarbonyl (C2-7 acyl) group" means the C2-7 acyl group substituted by the C2-7 alkoxycarbonyl group; the term "C 1-6 alkoxy (C 2-7 alkoxycarbonyl)" means the group C 2-7 alkoxycarbonyl substituted by the group Ci-e alkoxy above. The term "(C2-7 acyloxy)" means a hydroxymethyl group substituted by the group C2-7 acyl above; the term "group 1 - (C2-acyloxy) ethyl" means a 1-hydroxyethyl group substituted by the group C2-7 acyl above; the term "C2-7 alkoxycarbonyl) oxymethyl group" means an O-substituted hydroxymethyl group by the above C2-7 alkoxycarbonyl group; the term "group 1 - [(C2-7 alkoxycarbonyl) oxy] ethyl "means a 1-hydroxyethyl substituted-O group by the C2-7 alkoxycarbonyl group, the term" (C3 cycloalkyl) oxycarbonyl group "means a cyclic alkoxycarbonyl group having the C3-7 cycloalkyl group; the term "(C3-7 cycloalkyl) oxycarbonyl-oxymethyl group" means an O-substituted hydroxymethyl group by the above (C3-cycloalkyl) oxycarbonyl group, and the term "group 1 - [(C3-cycloalkyl) oxycarbonyloxy] ethyl" sig In addition, as a group for forming a prodrug, a glucopyranosyl group or a galactopyranosyl group can be exemplified by the above group (C-7 cycloalkyl) oxycarbonyl, for example, these groups are preferably introduced in the hydroxy group in the 4 or 6 position of the glucopyranosyloxy group or the galactopyranosyloxy group, and more preferably is introduced into the hydroxy group in the 4 or 6 position of the glucopyranosyloxy group. fused cos represented by the general formula (I) above of the present invention, for example, showed potent inhibitory activity in human SGLT1 or SGLT2 in a confirmatory test of human SGLT1 or SGLT2 inhibitory activity as will be described below. Accordingly, a fused heterocyclic derivative represented by the general formula (I) above of the present invention, can exert an excellent inhibitory activity of SGLT1 in the small intestine or an excellent SG LT2 inhibitory activity in the kidney, and inhibit significantly the increase in glucose level blood or significantly lower the blood glucose level. Accordingly, a fused heterocyclic derivative represented by the general formula (I) above of the present invention, can exert an excellent inhibitory activity of SGLT1 in the small intestine or an excellent inhibitory activity of SGLT2 in the kidney, and significantly inhibit the Increase in blood glucose level or significantly lower blood glucose level. Accordingly, a fused heterocyclic derivative represented by the above general formula (I) of the present invention, a pharmaceutically acceptable salt thereof and a prodrug thereof is extremely useful., in the form of an agent for the inhibition of postprandial hypergiucemia, the inhibition of progression in diabetes in a subject with glucose intolerance and the prevention or treatment of a disease associated with hypergiucemia such as diabetes, glucose intolerance (IGT) , diabetic complications (for example, retinopathy, neuropathy, nephropathy, ulcer, macroangiopathy), obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disease, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia, gout or the like, which is related to SGLT1 activity in the small intestine and SGLT2 activity in the kidney. In addition, the compounds of the present invention can be used suitably in combination with at least one selected member of the following drugs. Examples of drugs that can be used in combination with the compounds of the present invention include an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an inhibitor of dipeptidyl peptidase IV, a protein tyrosine phosphatase-1 B inhibitor, an inhibitor of glycogen phosphorylase, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic glycogenesis inhibitor, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, peptide- 1 glucagon type, glucagon-like peptide-1 analog, glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an inhibitor of aldose reductase, inhibitor of advanced glycation by-product formation, a protein C kinase inhibitor, a gamma-aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcription factor inhibitor NF-kB, a lipid peroxidase inhibitor, a n-acetylated acid-bound dipeptidase inhibitor, insulin-like growth factor-1, platelet-derived growth factor (PDGF), a platelet-derived growth factor (PDGF) analogue (eg, example, PDGF-AA, PDGF-BB, PDGF-AB), epidermal growth factor (EGF), factor of nerve growth, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EG B-761, bimoclomol insulin-enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SG LT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a phosphatase-1 B inhibitor, protein tyrosine, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroin-3, a kinase-3 inhibitor of glycogen synthase, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an inhibitor, aldose reductase inhibitor, an inhibitor of advanced glycation end-product formation, a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, an N-factor F-kB inhibitor, transcription, a lipid protease inhibitor, an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analog, factor of epidermal growth, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EG B-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartic, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a receptor agonist thyroid hormone, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a receptor enhancer of low density lipoprotein, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, an inhibitor of cholesterol ester transferase protein, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, an acid synthesis inhibitor uric acid, an uricosuric agent and an alkalinized urinary. In the case of uses of the compound of the present invention in combination with one or more prior drugs, the present invention includes any dosage forms for simultaneous administration as a single preparation or separate preparations in the form of the same route or a different route of administration, and administration at different dosage intervals as separate preparations in the form of the same route or a different administration route. A pharmaceutical combination comprising the compound of the present invention and the above drug (s) includes both dosage forms in the form of a single preparation, and separate preparations for combination, as mentioned above. The compounds of the present invention can obtain more convenient effects, than the additive effects in the prevention or treatment of the above diseases, when they are used in a suitable manner in combination with the one or more drugs described above. Also, the administration dose can be decreased compared to the administration of any drug alone, or the adverse effects of coadministration of the drugs can be avoided or diminished. The particular compounds in the form of drugs used for combination, and the preferred diseases to be treated are exemplified as indicated below. However, the present invention is not limited to this, and the particular compounds include their free compounds, and their pharmaceutically acceptable salts as well as others. As insulin sensitivity enhancers, receptor-agonists can be used. activated by proliferator peroxisome such as troglitazone, pioglitazone hydrochloride, rosiglitazone maleate, sodium darglitazone, GI-262570, isaglitazone, LG-100641, NC-2100, T-174, DRF-2189, CLX-0921, CS-01 1, GW- 1929, ciglitazone, sodium englitazone and NIP-221, peroxisome proliferator-activated receptor-a agonists such as GW-9578 and BM-170774, receptor-a / agonists. peroxisome proliferator-activated such as GW-409544, KRP-297, NN-622, CLX-0940, LR-90, SB-219994, DRF-4158 and DRF-MDX8, retinoid X receptor agonists such as ALRT-268, AGN-4204, MX-6054, AGN-194204, LG-100754 and bexarotene, and other insulin sensitivity enhancers such as reglixan, ONO-5816, MBX-102, CRE-1625, FK-614, CLX-0901, CRE -1633, NN-2344, BM-13125, BM-501050, HQL-975, CLX-0900, MBX-668, MBX-675, S-15261, GW-544, AZ-242, LY-510929, AR-H049020 and GW-501516. Insulin sensitivity enhancers are preferably used for diabetes, glucose intolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism and atherosclerosis, and more preferably for diabetes, glucose intolerance and hyperinsulinemia because they improve the disturbance of insulin signal transduction in peripheral tissues and increase the uptake of glucose in the blood tissues, leading to a decrease in the blood glucose level. As inhibitors of glucose uptake, for example, α-glucosidase inhibitors such as acarbose, voglibose, miglitol, CKD-71 1, emiglitato, MDL-25,637, camiglibose, and MDL-73,945, α-amylase inhibitors such as AZM-127, SGLT1 inhibitors that are described in the pamphlets of International Publications Nos. WO02 / 098893 and WO2004 / 014932, and the like. The glucose absorption inhibitors are preferably used for diabetes, glucose intolerance, diabetic complications, obesity or hyperinsulinemia, and more preferably for glucose intolerance due to the inhibition of the gastrointestinal enzymatic digestion of carbohydrates contained in food, and the inhibition or delay in the absorption of glucose in the body. In the form of biguanides, phenformin, buformin hydrochloride, metformin hydrochloride or the like can be illustrated. The biguanides are preferably used for diabetes, glucose intolerance, diabetic complications or hyperinsulinemia, and more preferably for diabetes, glucose intolerance or hyperinsulinemia due to the decrease in blood glucose level through the inhibitory effects on hepatic gluconeogenesis, accelerating the effects on anaerobic glycolysis in tissues or improving the effects on insulin resistance in peripheral tissues.

As enhancers of insulin secretion, tolbutamide, chlorpropamide, tolazamide, acetohexamide, gluclopyramide, glyburide (glibenclamide), gliclazide, 1-butyl-3-methanediylurea, carbutamide, glibornuride, glipizide, gliquidone, glisoxepide, glibutiazole, glibuzole, glihexamide can be illustrated , sodium glimidine, glipinamide, penbutamide, tolciclamide, glimepiride, nateglinide, calcium hydrate of metiglinide, repaglinide, or the like. In addition, insulin secretion enhancers include glucokinase activators such as RO-28-1 675. Insulin secretion enhancers are preferably used for diabetes, glucose intolerance or diabetic complications, and more preferably for diabetes or intolerance to glucose due to decreased blood glucose acting on pancreatic β-cells and increasing insulin secretion. As SGLT2 inhibitors, T-1 095 and the compounds described in Japanese Patent Publications No. Hei 1 0-237089 and 2001 -2881 78, and in International Publications Nos. WO01 / 1 6147, WO01 can be illustrated. / 271 28, WO01 / 68660, WO01 / 74834, WO01 / 74835, WO02 / 28872, WO02 / 36602, WO02 / 441 92, WO02 / 53573, WO03 / 000712, WO03 / 020737 and the like. SGLT2 inhibitors are preferably used for diabetes, glucose intolerance, diabetic complications, obesity or hyperinsulinemia, and more preferably for diabetes, glucose intolerance, obesity or hyperinsulinemia due to decreased blood glucose level, inhibiting glucose reabsorption and the proximal kidney tubule. As insulin or insulin analogs, human insulin, insulin derived from animal, human insulin analogs or animal derivatives or the like can be illustrated. These preparations are preferably used for diabetes, glucose intolerance or diabetic complications, and more preferably for diabetes or glucose intolerance. As antagonists of the glucagon receptor, BAY-27-9955, N-NC-92-1 687 or the like can be illustrated; As stimulants of insulin receptor kinase, TER-1741 1, L-783281, KRX-61 3 or the like can be illustrated; as inhibitors of tripeptidyl peptide I I, UCL-1 397 or the like can be illustrated; as inhibitors of dipeptidyl peptidase IV, IV, NVP-DPP728A, TSL-225, P-32/98 or the like can be illustrated; as inhibitors of protein tyrosine phosphatase 1 B, PTP-1 12, OC-86839, PN U-1 77496 or the like can be illustrated; as inhibitors of glycogen phosphorylase, one can illustrate NN-4201, CP-368296 or the like; as fructose bisphosphatase inhibitors, R-1 3291 7 or the like can be illustrated; as inhibitors of pyruvate dehydrogenase, AZD-7545 or the like can be illustrated; as inhibitors of hepatic gluconeogenesis, FR-225659 or the like can be illustrated; as glucagon-like peptide-1 analogs, hexenedin-4, CJC-1 1 31 or the like can be illustrated; as glucagon-like peptide-1 agonists; AZM-1 34, LY-31 5902 or the like can be illustrated; and as amylin, amylin analogs or amylin agonists, pramlintide acetate or the like can be illustrated. These drugs, glucose-6-phosphatase inhibitors, D-chiro-initol, inhibitors of glycogen synthase kinase-3 and glucagon-like peptide-1 are preferably used for diabetes, glucose intolerance, diabetic complications or hyperinsulinemia, and more preferably for diabetes or intolerance to glucose. As inhibitors of aldose reductase, asmobilite, tolrestat, epalrestat, DNA-138, BAL-ARI8, ZD-5522, DNA-31 1, GP-1447, I DD-598, fiderestat, sorbinil, ponalrestat, risarestat, zenarestat, minalrestat, metosorbinil, AL-1567, imirestat, M-16209, TAT, AD-5467, zopolrestat, AS-3201, NZ-314, SG-210, JTT-81 1, Lindolrestat or the like. Aldose reductase inhibitors are preferably used for diabetic complications due to the inhibition of aldose reductase and to the reduction of excessive intracellular accumulation of sorbitol in the accelerated polyol path, where the inhibitors are in a continuous hyperglycemic condition in the tissues in diabetic complications. As inhibitors of advanced glycation by-product formation, pyridoxamine, OPB-9195, ALT-946, ALT-71 1, pimagedine hydrochloride or the like are illustrated. The inhibitors of advanced glycation by-product formation are preferably used for diabetic complications due to the inhibition of formation of advanced glycation byproducts, which are accelerated in the hyperglycemic continuous condition in diabetes and in the reduction of cell damage. As inhibitors of protein C kinase, LY-333531, midostaurin or the like are illustrated. Protein C kinase inhibitors are preferably used for diabetic complications due to the inhibition of the kinase activity of Protein C, which accelerates in a hyperglycemic continuous condition in diabetes. As antagonists of the α-aminobutyric acid receptor, topiramate or the like is illustrated; as antagonists of the sodium channel, mexiletine hydrochloride, oxcarbazepine, or the like are illustrated; as inhibitors of the transcription factor NF-kB, dexlipotam or the like is illustrated; as lipid peroxidase inhibitors, tirilazad mesylate or the like is illustrated; as inhibitors of dipeptidase of linked-to-N-acetylated acid, GPI-5693 or the like; and as carnitine derivatives, carnitine, levacecarnine hydrochloride, levocarnitine hydrochloride, levocarnitine, ST-261 or the like are illustrated. These prodrugs, insulin-like growth factor-1, platelet-derived growth factor, platelet-derived growth factor analogs, epidermal growth factor, nerve growth factor, uridine, 5-hydroxy-1 -methylhydantoin, EGB-761, bimoclomol, sulodexide and Y-128 are preferably used for diabetic complications. As antidiarrheals or cathartics, polycarbophil calcium, albumin tannate, bismuth subnitrate or the like are illustrated. These drugs are preferably used for diarrhea, constipation or the like that accompany diabetes, or the like. As coenzyme A reductase inhibitors of hydroxymethylglutaryl, sodium cerivastatin, pravastatin sodium, levostatin, simvastatin, fluvastatin sodium, atorvastatin calcium hydrate, SC-45355, SQ-33600, CP-83101, BB-476, are illustrated. L- 669262, S-2468, DMP-565, U-20685, BAY-x-2678, BAY-10-2987, calcium pivastatin, calcium rosuvastatin, colestolone, dalvastatin, acytemate, mevastatin, crilvastatin, BMS-180431, BMY- 21,950, glenvastatin, carvastatin, BMY-22089, bervastatin or the like. Coenzyme A reductase inhibitors of hydroxymethylglutaryl are preferably used for hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorder or atherosclerosis, and more preferably for hyperlipidemia, hypercholesterolemia or atherosclerosis due to the decrease in blood cholesterol level by inhibiting coenzyme reductase A of hydroxymethylglutaryl. As fibrates, bezafibrate, beclobrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, aluminum clofibrate, clofibric acid, etofibrate, fenofibrate, gemfibrozil, nicofibrate, pirifibrate, ronifibrate, simfibrate, theofibrate, AHL-157 or the like are illustrated. Fibrates are preferably used for hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorder or atherosclerosis, and more preferably for hyperlipidemia, hypertriglyceridemia, or atherosclerosis, due to the activation of hepatic lipoprotein lipase and the increase of fatty acid oxidation , leading to a decrease in the level of triglycerides in the blood. As β 3 -adrenoceptor agonists, BRL-28410, SR-5861 1 A, ICI-198157, ZD-2079, BMS-194449, BRL-37344, CP-331679, CP-1 14271, L-750355, BMS are illustrated -187413, SR-59062A, BMS-210285, LY- 377604, SWR-0342SA, AZ-40140, SB-226552, D-71 14, BRL-35135, FR-1491 75, BRL-26830A, CL-31 6243, AJ-9677, GW-427353, N-5984, GW -2696, YM 1 78 or similar. The β 3 -adrenoceptor agonists are preferably used for obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, or lipid metabolism disorder, and more preferably for obesity or hyperinsulinemia due to the stimulation of adrenoceptor-3 in adipose tissue and increase oxidation of fatty acid, leading to induction of energy expenditure. As acyl cholesterol-coenzyme A acyltransferase inhibitors, NTE-1 22, MCC-147, PD-1 32301 -2, DU P-129, U-73482, U-76807, RP-70676, P- are illustrated. 061 39, CP-1 13818, RP-73163, FR-1 291 69, FY-038, EAB-309, KY-455, LS-31 1 5, FR-145237, T-2591, J-1 041 27 R -755, FCE-28654, YI C-C8-434, avasimibe, CI-976, RP-64477, F-1 394, eldacimibe, CS-505, CL-283546, YM-1 7E, lecimibe, 447C88, YM-750, E-5324, KW-3033, HL-004, eflucimibe or similar. Acyl cholesterol coenzyme A acyltransferase inhibitors are preferably used for hyperlipidemia, hypercholesterolemia, hypertriglyceridemia or lipid metabolism disorder, and more preferably for hyperlipidemia or hypercholesterolemia due to the decrease in blood cholesterol level by inhibiting acyl cholesterol acyltransferase. coenzyme A. In the form of thyroid hormone receptor agonists, sodium liothyronine, sodium levothyroxine, KB-261 1 or the like are illustrated.; as inhibitors of cholesterol absorption, are illustrated ezetimibe, SCH-48461 or the like; as lipase inhibitors, orlistat, ATL-962, AZM-1 31, RED-1 03004 or the like are illustrated; as carnitine palmitoyltransferase inhibitors, ethomoxir or the like; As squalene synthase inhibitors, SDZ-268-1 98, BMS-1 88494, A-87049, RPR-1 01 821, ZD-9720, RPR-1 07393, ER-27856, TAK-475 or the like are illustrated.; as nicotinic acid derivatives, nicotinic acid, nicotinamide, nicomol, niceritol, acipimox, nicorandil or the like are illustrated; as bile acid sequestrants, cholestyramine, cholestylan, coleseveiam hydrochloride, GT-1 02-279 or the like are illustrated; as inhibitors of the bile acid / sodium cotransporter, 264W94, S-8921, SD-561 3 or the like are illustrated; and as inhibitors of cholesterol ester transferase protein, PNU-1 07368E, SC-795, JTT-705, CP-529414 or the like are illustrated. These drugs, probcol, inhibitors of microsomal triglyceride transferase protein, lipoxygenase inhibitors and low density lipoprotein receptor enhancers are preferably used for hyperiipidemia, hypercholesterolemia, hypertriglyceridemia or lipid metabolism disorders. As appetite suppressants, monoamine reuptake inhibitors, serotonin reuptake inhibitors, serotonin releasing stimulants, serotonin agonists (especially 5HT2c agonists), norepinephrine reuptake inhibitors, norepinephrine release stimulants, ai-adrenoceptor, ß2.adrenoceptor agonists, dopamine agonists, cannabinoid receptor antagonists, α-aminobutyric acid receptor antagonists, H-histamine antagonists, L-histidine, leptin, leptin analogs, leptin receptor agonists, melanocortin receptor agonists (especially, MC3-R agonists, MC4-R agonists), a-melanocyte stimulation hormone, transcription regulated by cocaine and amphetamine, mahogani protein, enterostatin agonists, calcitonin, peptide related to calcitonin gene, bombesin, cholecystokinin agonists (especially CCK-A agonists), corticotropin releasing hormone, corticotropin-releasing hormone analogues, corticotropin-releasing hormone agonists, urocortin, somatostatin, somatostatin analogues, somatostatin receptor agonists, pituitary adenylate cyclase activation peptide, brain-derived neurotrophic factor, neurotrophic factor ciliary, thyrotropin releasing hormone, neurotensin, sauvagina, neuroprotec antagonists and Y, opioid peptide antagonists, galanin antagonists, melanin concentration hormone receptor antagonists, agouti-related protein inhibitors, and orexin receptor antagonists. In particular, as monoamine reuptake inhibitors, mazindol or the like is illustrated; As inhibitors of serotonin reuptake, fenfluramine hydrochloride, fenfluramine, sibutramine hydrochloride, fluvoxamine maleate, sertraline hydrochloride or the like are illustrated; as serotonin agonists, inotriptan, (+) - norfenfluramine or the like are illustrated; as inhibitors of noradrenaline reuptake, are illustrated bupropion, GW-320659 or the like; as stimulants for noradrenaline release, rolipram, YW-992 or the like are illustrated; as β2-adrenoceptor agonists, amphetamine, dextroamphetamine, phentermine, benzfetamine, methamphetamine, phendimetrazine, phenmetrazine, diethylpropion, phenylpropanolamine, clobenzorex or the like are illustrated; as dopamine agonists, ER-230, doprexin, bromocriptine mesylate, or the like are illustrated; as cannabinoid receptor antagonists, rimonabant or the like are illustrated; as α-aminobutyric acid receptor antagonists, topiramate or the like are illustrated; as H 3 -histamine antagonists, GT-2394 or the like are illustrated; such as leptin, leptin analogs or leptin receptor agonists, LY-355101 or the like are illustrated; as cholecystokinin agonists (especially agonists CCK-A), SR-146131, SSR-125180, BP-3200, A-71623, FPL-15849, GI-248573, GW-7178, GI-181771, GW-7854, are illustrated. A-71378 or the like; and as neuropeptide Y antagonists, SR-120819-A, PD-160170, NGD-95-1, BIBP-3226, 1229-U-91, CGP-71683, BIBO-3304, CP-671906-01, J are illustrated. -1 15814 or similar. Appetite suppressants are preferably used for diabetes, glucose intolerance, diabetic complications, obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disease, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia or gout, and more preferably for obesity due to stimulation or inhibition of intracerebral monoamine or peptide activities bioactive in the central appetite regulator system and suppressing the appetite, leading to a reduction of energy intake. As inhibitors of angiotensin converting enzyme, captopril, enalaprimaleate, alacepril, delapril hydrochloride, ramipril, lisinopril, imidapril hydrochloride, benazepril hydrochloride, ceronapril monohydrate, cilazapril, sodium fosinopril, perindopril erbumin, calcium moveltipril are illustrated. , quinapril hydrochloride, spirapril hydrochloride, temocapril hydrochloride, trandolapril, calcium zofenopril, moexipril hydrochloride, rentiapril or the like. Angiotensin-converting enzyme inhibitors are preferably used for diabetic complications or hypertension. As inhibitors of neutral endopeptidase, omapatrilat, MDL-100240, fasidotril, sampatrilat, GW-66051 1 X, mixanpril, SA-7060, E-4030, SLV-306, ecadotril or the like are illustrated. Inhibitors of neutral endopeptidase are preferably used for diabetic complications or hypertension. As angiotensin II receptor antagonists, candesartan cilexetil, candesartan cilexetil / hydrochlorothiazide, potassium losartan, eprosartan mesylate, valsaran, telmisarfan, irbesartan, EXP-3174, L-158809, EXP-3312, olmesartan, tasosartan, are illustrated. KT-3-671, GA-01 13, RU-64276, EMD-90423, ER-9701 or the like. Angiotensin II receptor antagonists are preferably used for diabetic complications or hypertension. As inhibitors of endothelin conversion enzyme, CGS-31447, CGS-35066, SM-19712 or the like are illustrated; as Endothelin receptor antagonists are illustrated L-749805, TBC-3214, BMS-182874, BQ-610, TA-0201, SB-215355, PD-180988, sodium sitaxsentan, BMS-193884, darusentan, TBC-371 1 , bosentan, sodium tezosentan, J-104132, YM-598, S-0139, SB-234551, RPR-1 18031A, ATZ-1993, RO-61-1790, ABT-546, enlasentan, BMS-207940 or the like. These drugs are preferably used for diabetic complications or hypertension, and more preferably for hypertension. As diuretic agents, chlorthalidone, metolazone, cyclopentiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, methyclothiazide, indapamide, tripamide, mefruside, azosemide, ethacrynic acid, torasemide, piretanide, furosemide, bumetanide, methicrane, potassium canreonate, spironolactone are illustrated. , triamterene, aminophylline, cyclintanin hydrochloride, LLU-a, PNU-80873A, isosorbide, D-mannitol, D-sorbitol, fructose, glycerin, acetazolamide, methazolamide, FR-179544, OPC-31260, lixivaptan, conivaptan hydrochloride or the like . Diuretic drugs are preferably used for diabetic complications, hypertension, congestive heart failure or edema, and more preferably for hypertension, congestive heart failure or edema due to the reduction of blood pressure or to improve edema by increasing urinary excretion. As calcium antagonists, aranidipine, efonidipine hydrochloride, nicardipine hydrochloride, hydrochloride barnidipine, benidipine hydrochloride, manidipine hydrochloride, cilnidipine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, amlodipine besylate, pranidipine, lercanidipine hydrochloride, isradipine, eldipipine, azelnidipine, lacidipine, vatanidipine hydrochloride, lemildipine, diltiazem hydrochloride, clentiazem maleate, verapamil hydrochloride, S-verapamil, fasudil hydrochloride, bepridil hydrochloride, gallopamil hydrochloride or the like; as vasodilation antihypertensive agents, indapamide, todralazine hydrochloride, hydralazine hydrochloride, cadralazine, budralazine, or the like are illustrated; as sympathetic blocking agents, amosulalol hydrochloride, terazosin hydrochloride, bunazosin hydrochloride, prazosin hydrochloride, doxazosin mesylate, propranolol hydrochloride, atenolol, metoprolol tartrate, carvedilol, nipradilol, celiprolol hydrochloride, nebivolol, hydrochloride betaxolol, pindolol, tertatolol hydrochloride, bevantolol hydrochloride, timolol maleate, carteolol hydrochloride, bisoprolol hemifumarate, bopindolol malonate, nipradilol, penbutolol sulfate, acetobutolol hydrochloride, tilisolol hydrochloride, nadolol, urapidil, indoramin or similar; as centrally acting antihypertensive agents, reserpine or the like is illustrated; and as a2-adrenoceptor agonists, clonidine hydrochloride, methyldopa, CHF-035, guanabenz acetate, guanfacine hydrochloride, moxonidine, lofexidine, talipexole hydrochloride or the like are illustrated. These drugs are preferably used for hypertension.

As antiplatelet agents, ticlopidine hydrochloride, dipyridamole, cilostazol, ethyl icosapentate, sarpogrelate hydrochloride, dilazep dihydrochloride, trapidil, beraprost sodium, aspirin or the like are illustrated. Antiplatelet agents are preferably used for atherosclerosis or congestive heart failure. As inhibitors of uric acid synthesis, allopurinol, oxipurinol, or the like are illustrated; as uricosuric agents, benzbromarone, probenecid or the like are illustrated; and as basic or alkaline, hydrogen or sodium carbonate, potassium citrate, sodium citrate or the like are illustrated. These drugs are preferably used for hyperuricemia or gout. In the case of uses in combination with a compound of the present invention, for example, in use for diabetes, combination with at least one member of the group consisting of an insulin sensitivity enhancer, an insulin absorption inhibitor, is preferred. glucose, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an inhibitor of dipeptidyl peptidase IV, a protein tyrosine phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, an inhibitor of hepatic gluconeogenesis, D-chiro-initol, an inhibitor of glycogen siRNA kinase-3, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist and an appetite suppressant; most preferred is the combination with at least one member of the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue , a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an inhibitor of dipeptidyl peptidase IV, a protein tyrosine phosphatase-1B inhibitor, a phosphorylase inhibitor of glycogen, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a peptide-1 glucagon type, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist and an appetite suppressant; and most preferably is the combination with at least one member of the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor and an insulin or insulin analogue. insulin. Similarly, in use for diabetic complications, combination with at least one member of the group consisting of insulin sensitivity enhancer, glucose uptake inhibitor, biguanide, insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an inhibitor of dipeptidyl peptidase IV, a protein tyrosine phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-inositol , a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analog, an amylin agonist, an aldose reductase inhibitor, an advanced glycation byproduct formation inhibitor, a protein C kinase inhibitor, an α-aminobutyric acid antagonist, a sodium channel antagonist , an inhibitor of the transcription factor NF-kB, an inhibitor of lipid peroxidase, an inhibitor of dipeptidase of acid bound with aN-acetylated, insulin-like growth factor-1, platelet-derived growth factor, growth factor analog platelet derivative, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrhoeal, cathartics, an inhibitor of angiotensin-converting enzyme, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, a conversion enzyme inhibitor of endothelin, an endothelin receptor antagonist and a diuretic agent; and the combination with at least one member of the group consisting of an aldose reductase inhibitor, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor and an angiotensin receptor I I antagonist is more preferable. Further, in the use for obesity, the combination with at least one member of the group consisting of insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, is preferable. an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an inhibitor of dipeptidyl peptidase IV, a phosphatase-IV protein tyrosine inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a glycogen synthase kinase-3 inhibitor , a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analog, an amylin agonist, an agonist ß3-adrenoceptor stan, and an appetite suppressant; and a combination with at least one member of the group consisting of a glucose uptake inhibitor, a SGLT2 inhibitor, a β3-adrenoceptor agonist and an appetite suppressant is more preferable. When the pharmaceutical compositions of the present When used in the practical treatment, various dosage forms are used depending on their uses. As examples of the dosage forms, powders, granules, fine granules, dry syrups, tablets, capsules, injections, solutions, ointments, suppositories and cataplasms and the like, which are administered orally or parenterally, are illustrated. The pharmaceutical compositions of the present invention also include sustained release formulation including gastrointestinal mucoadhesive formulation (e.g., International Publication Nos. WO99 / 10010, WO99 / 26606, and Japanese Patent Publication No. 2001 -2567). These pharmaceutical compositions can be prepared by mixing in additions, or diluting and dissolving with a suitable pharmaceutical additive such as excipients, disintegrants, binders, lubricants, diluents, buffers, isotonifiers, antiseptics, wetting agents, emulsifiers, dispersing agents, stabilizing agents. , auxiliaries in solution and the like, and formulating the mixture according to conventional methods. In case the uses of the compound of the present invention in combination with another drug (s) can be prepared by formulating each active ingredient together or individually in a similar manner as defined above. When the pharmaceutical compositions of the present invention are employed in the practical treatment, the dosage of a compound represented by the general formula (I) above, a pharmaceutically acceptable salt thereof or a prodrug thereof as the active ingredient, the decision is taken appropriately depending on the age, sex, body weight and degree of symptoms and treatment of each patient, wherein the dosage is approximately in the range of 0.1 to 1, 000 mg per day per human adult in the case of oral administration, approximately within the range of 0.01 to 300 mg per day per human adult in the case of parenteral administration, and the daily dose can be divided into one to several doses per day and administered in an appropriate manner. Also, in the case of the uses of the compound of the present invention in combination with another drug (s), the dose of the compound of the present invention can be decreased, depending on the dose of the drug (s). EXAMPLES The present invention is further illustrated in greater detail by way of the following Reference Examples, Examples and Test Examples. However, the present invention is not limited to these. Reference Example 1 2-bromo-6-fluorobenzaldehyde To a solution of diisopropylamine (2.65 ml) in tetrahydrofuran (30 ml), n-butyllithium (2.44 mol / L n-hexane solution, 7.03 ml) was added to a temperature of -78 ° C under an argon atmosphere, and the mixture was stirred at the same temperature for 5 minutes. To the reaction mixture was added 3-bromofluorobenzene (3 g), and the mixture was stirred at the same temperature for 1 hour. To the reaction mixture, N, N-dimethylformamide (81.45 ml) was added, and the mixture was stirred at the same temperature for 10 minutes, then an aqueous solution of saturated ammonium chloride was added, and the mixture was stirred. stirred under cooling with ice for 5 minutes. The mixture was poured into water, and the mixture was extracted with diethyl ether. The extract was washed with water and brine and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to yield the title compound (3.43 g). 1 H-RM N (CDCl 3) d ppm: 7.1 -7.2 (1 H, m), 7.35-7.45 (1 H, m), 7.45-7.55 (1 H, m), 1 0.36 (1 H, s). Reference Example 2 4-bromobenzofibenophen To a suspension of sodium hydride (55%, 1.1 g) in dimethyl sulfoxide (20 ml), methyl thioglycolate (1.53 ml) was added at room temperature, and the mixture was stirred for 15 minutes. A solution of 2-bromo-6-fluorobenzaldehyde (3.43 g) in dimethyl sulfoxide (4 ml) was added to the reaction mixture, and the mixture was stirred at room temperature for 5 minutes. The reaction mixture was poured into ice water and the precipitated crystalline solid was collected by filtration, washed with water and dried under reduced pressure to yield 2-methoxycarbonyl-4-bromobenzo [b] thiophene (1.52 g). This material was suspended in a mixed solvent of methanol (20 ml) and water (10 ml) and sodium hydroxide (0.91 g) was added to the suspension. The mixture was stirred at a temperature of 50 ° C for 5 hours. The reaction mixture was cooled with an ice bath, and the reaction mixture was acidified by adding 2 mol / L hydrochloric acid. The precipitated crystalline solid was collected by filtration, washed with water and dried under reduced pressure to yield 2-carboxybenzo [b] thiophene (1.27 g). To this material were added copper powder (0.42 g) and quinoline (10 ml), and the mixture was stirred at a temperature of 1 90 ° C for 1 hour. After the reaction mixture was cooled to room temperature, 2 mol / L hydrochloric acid (40 mL) and ethyl acetate (20 mL) were stirred for 1 5 minutes, and the mixture was stirred for 15 minutes. The insoluble material in the mixture was removed by filtration, and the organic layer of the filtrate was separated. The aqueous layer of the filtrate was extracted with ethyl acetate. The organic layers were combined, and the combined organic layer was washed with 2 mol / L hydrochloric acid, water and brine and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: n-hexane) to yield the title compound (0.55 g). 1 H-RM N (CDCl 3) d ppm: 7.1 5-7.25 (1 H, m), 7.45-7.6 (3H, m), 7.82 (1 H, d, J = 8.2 Hz). Reference Example 3 7-bromobenzob] thiophene To a mixture of 2-bromothiophenol (5 g) and 2-bromomethyl-1,3-dioxolane (2.98 ml) in N, N-dimethylformamide (50 ml), potassium carbonate (5.48 g) was added at room temperature, and the mixture was stirred overnight. The reaction mixture was poured into water, and the mixture was extracted with diethyl ether. The extract was washed with water, 1 mol / L of an aqueous solution of sodium hydroxide, water and brine in succession, and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to produce (2-bromophenylthiomethyl) ) -1, 3-dioxolane (7.25 g). To a mixture of polyphosphoric acid (20 g) and chlorobenzene (40 ml), was added a solution of (2-bromophenyl) -thiomethyl) -1,3-dioxolane (7.25 g) in chlorobenzene (20 ml), and the The mixture was refluxed for 8 hours. The reaction mixture was cooled to room temperature and the supernatant solution was collected by decantation. Toluene was added to the residue, and the supernatant was collected by decanting after the mixture was stirred. The supernatant was combined and concentrated under reduced pressure. The residue was dissolved in ethyl acetate, and the solution was washed with an aqueous solution of saturated sodium hydrogencarbonate, water and brine and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: n-hexane) to yield the title compound (2.27 g). 1 H-NMR (CDCl 3) d ppm: 7.25 (1 H, t, J = 7.8 Hz), 7.44 (1 H, d, J = 5.6 Hz), 7.45-7.55 (2H, m), 7. 77 (1 H, d, J = 7.8 Hz). Reference Example 4 4-r (E) -2-phenylvinyl-1-benzo [b1-thiophene To a mixture of 4-bromobenzo [b] thiophene (0.55 g), styrene (0.99 ml), triethylamine (1.81 ml), Palladium (II) (59 mg), and tris (2-methylphenyl) phosphine (0.1 6 g) in acetonitrile (10 ml) was refluxed overnight under an argon atmosphere. The reaction mixture was diluted with diethyl ether and an insoluble material was removed by filtration. The filtrate was washed with 1 mol / L hydrochloric acid, water and brine successively, and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure.

The residue was purified by column chromatography on silica gel (eluent: n-hexane-n-hexane / ethyl acetate = 5/1) to yield the title compound (0.56 g). 1 H-NMR (CDCl 3) d ppm: 7.2-7.45 (6H, m), 7.51 (1 H, d, J = 5.5 Hz), 7.55-7.7 (4H, m), 7.81 (1 H, d, J = 7.8 Hz). Reference Example 5-α (E) -2-phenylvinipbenzo [bltiofen] The title compound was prepared in a manner similar to that described in Reference Example 4, using 7-bromobenzo [b] thiophene instead of 4 -bromobenzo [b] thiophene. 7. 25-7.45 (7H, m), 7.5 (1 H, d, J = 5.7 Hz), 7.55-7.65 (3H, m), 7.77 (1 H, dd, J = 7.9 Hz, 1 .1 Hz).

Reference Example 6 4- (2-phenylethyl) benzofethiofen To a solution of 4 - [(E) -2-phenylvinyl] benzo [b] thiophene (0.56 g) and triethyl amine (2.63 ml) in tetrahydrofuran (25 ml) , 2,4,6-triisopropylbenzenesulfonylhydrazide (5 g) was added and the mixture was refluxed overnight under an argon atmosphere. Once the reaction mixture was used at room temperature, 2 mol / L hydrochloric acid was added to the mixture, and the mixture was stirred for 10 minutes. The mixture was poured into water and the mixture was extracted with diethyl ether. The extract was washed with water and brine and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: n-hexane) to give a mixture of the starting material and the title compound (0.43 g). This mixture was dissolved in triethylamine (2.04 g) and tetrahydrofuran (18 ml), and 2,4,6-triisopropylbenzenesulfonylhydrazide (3.28 g) was added to the solution, and the mixture was refluxed overnight under an argon atmosphere. . The reaction mixture was cooled to room temperature and 2 mol / L hydrochloric acid was added to the mixture, and the mixture was stirred for 10 minutes. The mixture was poured into water, and the mixture was extracted with diethyl ether. The extract was washed with water and brine and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by chromatography on silica gel (eluent: n-hexane) to yield the compound of the title (0.4 g). 3. 0-3.05 (2H, m), 3.2-3.3 (2H, m), 7.1 -7.35 (7H, m), 7.4-7.5 (2H, m), 7.75 (1H, d, H = 8.0 Hz). Reference Example 7 7- (2-phenylethylbenzorbothiophene) The title compound was prepared in a manner similar to that described in Reference Example 6, using 7 - [(E) -2-phenyl-vinyl] benzo [b] thiophene instead of 4 - [(E) -2-phenylvinyl] benzo [b] thiophene. 1 H-NMR (CDCl 3) d ppm: 3.05-3.15 (2H, m), 3.15-3.25 (2H, m), 7.1 - 7.35 (7H, m), 7.38 (1 H, d, J = 5.4 Hz), 7.44 (1 H, d, J = 5.4 Hz), 7.7 (1 H, d, J = 7.9 Hz) Reference Example 8 2- (2,3,4,6-tetra-O-benzyl-β-D-qylopyranosyl) -4- (2-phenylethylbenzoyltiofen) To a solution of 4- (2-phenylethyl) benzo [b] thiophene (0.4 g) in tetrahydrofuran (15 mL), n-butyllithium (2.44 mol / L n-hexane solution, 0.69 mL) was added at a temperature of -78 ° C under an argon atmosphere, and the mixture was stirred at room temperature. the same temperature for 30 minutes A solution of 2,3,4,6-tetra-O-benzyl-D-glucono-1,5-lactone (0.82 g) in tetrahydrofuran (3 ml) was added to the mixture, and The mixture was stirred under cooling with ice for 10 min. The reaction mixture was poured into an aqueous solution of saturated ammonium chloride, and the mixture was extracted with diethyl ether. The extract was washed with water and brine and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: n-hexane / ethyl acetate = 4/1) to yield 2,3,4,6-tetra-O-benzyl-1- [4- (2 phenylethyl) benzo [b] thiophen-2-yl] -D-glucopyranose (1.02 g). This material was dissolved in acetonitrile (13 ml) and triethylsilane (0.42 ml) was added to the solution. A complex of diethyl ether-boron trifluoride (0.18 ml) was added to the solution at a temperature of -20 ° C, and the mixture was stirred at room temperature for 1 hour. An aqueous solution of saturated potassium carbonate was added to the reaction mixture, and the mixture was extracted with diethyl ether. The extract was washed with water and brine and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: n-hexane / ethyl acetate = 8/1) to give the title compound (0.58 g). 1 H-NMR (CDCl 3) d ppm: 2.9-3.05 (2H, m), 3.1-3.25 (2H, m), 3.6-3.7 (2H, m), 3.75-3.9 (4H, m), 4.11 (1H, d , J = 10.4 Hz), 4.55-4.75 (5H, m), 4.88 (1H, d, J = 10.7 Hz), 4.92 (1H, d, J = 11.0 Hz), 4.96 (1H, d, J = 11.0 Hz ), 6.9-7.0 (2H, m), 7.05-7.4 (25H, m), 7.47 (1H, s), 7.7 (1H, d, J = 8.1 Hz). Reference Example 9 2- (2.3.4.6-tetra-O-benzyl-β-D-alucopyranos) n-7- (2-phenyl-ethipbenzofbltiofen) The title compound was prepared in a manner similar to that described in Reference Example 9, using 7- (2-phenylethyl) benzo [b] thiophene in place of 4- (2-phenylethyl) benzo [b] thiophene. 1 H-NMR (CDCU) d ppm: 3.0-3.2 (4H, m), 3.6-3.7 (2H, m), 3.75-3.9 (4H, m), 4.11 (1H, d, J = 10.3 Hz), 4.5- 4.75 (5H, m), 4.87 (1H, d, J = 10.7 Hz), 4.92 (1H, d, J = 11.0 Hz), 4.97 (1H, d, J = 11.0 Hz), 6.95-7.0 (2H, m ), 7.1-7.45 (26H, m), 7.62 (1H, d, J = 7.8 Hz). Example 1 2- (β-D-qylopyranosyl) -4- (2-phenylethyl) benzo [β1-thiophene to a solution of 2-82, 3,4,6-tetra-O-benzyl-β-D-glucopyranosyl) -4- (2-phenylethyl) benzo [b] thiophene (0.58 g) and ethanethiol (1.13 ml) in dichloromethane (10 ml), a complex of diethyl ether-boron trifluoride (1.43 ml) was added at room temperature, and the mixture was stirred for 3 hours. An aqueous solution of saturated potassium carbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with brine and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: dichloromethane / methanol = 10/1) to yield the title compound (94 mg). 2. 95-3.05 (2H, m), 3.15-3.25 (2H, m), 3.35-3.55 (4H, m), 3.72 (1H, dd, J = 12.1 Hz, 6.0 Hz), 3.92 (1H, dd, J = 12.1 Hz, 2.1 Hz), 4.55 (1H, d, J = 8.8 Hz), 7.06 (1H, d, J = 6.8 Hz), 7.1-7.3 (6H, m), 7.54 (1 H, s), 7.66 (1 H, d, J = 8.3 Hz). Example 2 2- (β-D-glucopyranosyl) -7- (2-phenylethylPenzo [b1thiophene] The title compound was prepared in a manner similar to that described in Example 1, using 2- (2,3, 4,6-tetra-O-benzyl-β-D-glucopyranosyl) -7- (2-phenylethyl) benzo [b] thiophene instead of 2- (2,3,4,6-tetra-O-benzyl-β -D-glucopyranosyl) -4- (2-phenylethyl) benzo [b] thiophene. 1 H-NMR (CDCl 3) d ppm: 3.0-3.1 (2H, m), 3.1 -3.2 (2H, m), 3.35-3.55 (4H, m), 3.73 (1 H, dd, J = 12. 1 Hz, 5.8 Hz), 3.93 (1 H, dd, J = 12.1 Hz, 2.0 Hz), 4.54 (1 H, d, J = 8. 6 Hz), 7.06 (1 H, d, J = 6.5 Hz), 7.1 -7.3 (6H, m), 7.41 (1 H, s), 7.55- 7.65 (1 H, m). Example 3 Process 1 Benzo [b1thiophen-7-yl-p-tolyl methanol A Grignard reagent was prepared using 7-bromobenzo [b] thiophene (1.0 g), magnesium (0.13 g), a catalytic amount of iodine and tetrahydrofuran ( 3 ml) according to the general method. To the Grignard reagent solution was added a solution of 4-methylbenzaldehyde (0.62 g) in tetrahydrofuran (5 ml) at a temperature of 0 ° C under an argon atmosphere. The reaction mixture was stirred at room temperature overnight and an aqueous solution of saturated ammonium chloride was added to the mixture. The mixture was extracted with diethyl ether, and the organic layer it was washed with brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on aminopropylated silica gel (eluent: tetrahydrofuran). Further purification by column chromatography on silica gel (eluent, n-hexane / ethyl acetate = 6/1), afforded the title compound (0.68 g) in the form of a yellow oil. 1 H-NMR (CDCl 3) d ppm: 2.32 (3H, s), 2.38 (1 H, d, J = 3.6 Hz), 6.1 1 (1 H, d, J = 3.4 Hz), 7.10-7.20 (2H, m), 7.30-7.45 (5H, m), 7.45-7.50 (1 H, m), 7.70-7.80 (1 H, m). Process 2 7- (4-methylbenzyl) benzoyl-1-thiophene To a suspension of sodium iodide (2.0 g) in acetonitrile was added chlorotrimethylsilane (1.5 g) at room temperature. After the mixture was stirred at room temperature for 15 minutes, benzo [b] thiophen-7-yl-p-tolylmethanol (0.68 g) was added to the mixture, and the mixture was stirred at room temperature for 15 minutes. The reaction mixture was poured into water, and the mixture was extracted with hexane. The organic layer was washed with water and brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: n-hexane) to yield the title compound (0.57 g) in the form of a colorless oil. 2. 31 (3H, s), 4.20 (2H, s), 7.05-7. 14 (3H, m), 7.14-7.20 (2H, m), 7. 25-7.45 (3H, m), 7.65-7.75 (1 H, m). Process 3 2.3.4.6-tetra-O-benzyl-1-r7- (4-methylbenzyl) benzorb] thiophen-2-ip-D-chloropyranose To a solution of 7- (4-methylbenzyl) benzo [b] thiophene (0.57 g) in tetrahydrofuran (10 ml), n-butyllithium (2.71 mol / L of tetrahydrofuran solution, 0.88 ml) was added at a temperature of -78 ° C under an argon atmosphere. The mixture was stirred at the same temperature for 30 minutes and a solution of 2,3,4,6-tetra-O-benzyl-D-glucono-1,5-lactone (1.2 g) in the mixture was added to the mixture. tetrahydrofuran (5 ml). The reaction mixture was warmed to a temperature of 0 ° C and stirred for 10 minutes. The reaction mixture was poured into an aqueous solution of saturated ammonium chloride, and the mixture was extracted with diethyl ether. The organic layer was washed with brine and dried over anhydrous magnesium sulfate.

The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: n-hexane / ethyl acetate = 4/1) to yield the title compound (1 -2 g). Process 4 2- (2.3.4.6-tetra-O-benzyl-β-D-alucopyranosyl) -7- (4-methylbenzyl) benzo [b1tiofen To a solution of 2,3,4,6-tetra-O-benzyl- 1 - [7- (4- methylbenzyl) benzo [b] thiophen-2-yl] -D-glucopyranose (1.2 g) and triethylsilane (0.49 ml) in acetonitrile (15 ml), a complex of diethyl ether-boron trifluoride (2.0 ml) was added. ) at a temperature of -20 ° C, and the mixture was stirred for 1 hour. An aqueous solution of saturated potassium carbonate was added to the mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: n-hexane / ethyl acetate = 6/1) to yield the title compound (0.95 g). 1 H-NMR (CDCl 3) d ppm: 2.28 (3H, s), 3.55-3.70 (2H, m), 3.75-3.85 (4H, m), 4.09 (1 H, d, J = 10.5 Hz), 4.15- 4.20 (2H, m), 4.52 (1 H, d, J = 10.4 Hz), 4.56-4.62 (2H, m), 4.62-4.72 (2H, m), 6.90-7.00 (2H, m), 7.00-7.40 (25H, m), 7.55-7.65 (1 H, m). Process 5 2- (ß-D-qylopyranosyl) -7- (4-methylbenzyl) benzorbltiophen A solution of 2- (2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl) - 7- (4-methylbenzyl) benzo [b] thiophene (0.95 g) and ethanethiol (1.8 ml) in dichloromethane (15 ml), was added a complex of diethyl ether-boron trifluoride (2.1 ml) at room temperature . The reaction mixture was stirred at room temperature for 3 hours, and an aqueous solution of saturated potassium carbonate was added to the mixture. The mixture was extracted with ethyl acetate. The organic layer was washed with brine and dried over magnesium sulfate anhydrous. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: dichloromethane / methanol = 10/1) to yield the title compound (0.16 g). 1 H-NMR (CDCl 3) d ppm: 2.27 (3H, s), 3.30-3.50 (4H, m), 3.69 (1H, dd, J = 5.9, 12.1 Hz), 3.90 (1H, dd, J = 2.0, 12.1 Hz), 4.10-4.15 (2H, m), 4.50 (1H, d, J = 9.0 Hz), 7.00-7.15 (5H, m), 7.25-7.35 (1H, m), 7.35-7.40 (1H, m) , 7.55-7.70 (1H, m). Example 4 - Example 11 The compounds described in Table 1 or 2 were prepared in a manner similar to that described in Example 3, using the corresponding starting materials.

[Table 1] [Table 2] Example 12 - Example 16 The compounds described in Table 3 or 4 were prepared in a manner similar to that described in Example 1, using the corresponding starting materials.

[Table 3] [Table 4] The compounds described in Table 5 can be prepared in a manner similar to those described in the above Examples or Reference Examples. [Table 5] Test Example 1 Ensave for inhibitory effects on SG LT1 h umana activity 1) Cloning and construction of the vector expressing human SG LT1 The cDNA library was prepared for PCR amplification by reverse transcription from total RNA devoid of human small intestine (gene Ori) using oligo-dT as a primer. Using this cDNA library as a template, it PCR amplified the DNA fragment coding from 1 to 2005 bp of human SGLT1 (ACCESS: M24847), which was reported by Hediger and associates, and inserted into the multiple cloning site of pcDNA3. 1 (-) (I nvitrogen). The inserted DNA sequence coincided perfectly with the sequence previously reported. 2) Establishment of cell line stably expressing human SGLT1 The expression vector of human SGLT1 was digested by Sea I in a linear DNA. Linear DNA was transfected into CHO-K1 cells by lipofection (Effectene Transfection Reagent: QIAGEN). The neomycin-resistant cell lines were selected by culture in a medium containing G41 8 (1 mg / mL, LI FE TECHNOLOGI ES), and subsequently the activity against the uptake of methyl-aD-glucopyranoside was measured by the method described later. The cell line, which showed the highest uptake activity, was selected and designated as CS 1 -5-1 1 D. CS 1-5-1 1 D cells were cultured in the presence of G41 8 at 200 μg / mL . 3) Measurement of the inhibitory activity against the uptake of methyl-aD-glucopyranoside (a-MG) CS 1 -5-1 1 D plates were seeded in a 96-well culture plate at a density of 3 X 1 04 cells / deposit and were cultured for 2 days, and used in the uptake assay. It was added to the uptake buffer (pH 7.4, which contains 140 mM of chloride of sodium, 2 mM of potassium chloride, 1 mM of calcium chloride, 1 mM of magnesium chloride, 10 mM of 2- [4- (2-hydroxyethyl) -1-piperazinyl] ethane sulfonic acid and 5 mM of tris (hydroxymethyl) aminomethane in the final concentration of 1 mM), a mixture of unlabeled a-MG (Sigma) and labeled-14C (Amersham Pharmacia Biotech). A test compound was dissolved in dimethyl sulfoxide, and subsequently adequately diluted with distilled water. The solution of the test compound was added to the uptake buffer containing 1 mM of α-MG, and was designated as a measuring regulator. For the control group, the measurement regulator was prepared without any test compound. To measure basal uptake, a basal uptake measurement regulator containing 140 mM chlorine chloride was prepared in place of sodium chloride. After removing the culture medium from the CS1 -5-1 1 D cells, 180 μl of the pretreatment regulator (the basal uptake buffer without a-MG) was added to each well and incubated at a temperature of 37 °. C for 10 minutes. After repeating the same treatment, the pre-treatment regulator was eliminated. To each deposit was added 75 μL of the measuring regulator or the basal uptake regulator was added and incubated at a temperature of 37 ° C for 1 hour. After removing the measuring regulator, the cells were washed twice with 180 μL per wash buffer reservoir (the basal uptake buffer containing 10 mM unlabeled a-MG). Cells were solubilized by 75 μL per 0.2 mol / L deposit of hydroxide of sodium. The cell lysates were transferred in PicoPlacas (Packard), and subsequently 150 μL of MicroScint-40 (Packard) were added and mixed. Radioactivity was measured by TopCount micro-scintillation counter (Packard). 100% was adjusted for the difference between the uptake in the control group and the basal uptake, and the uptake of methyl α-D-glucopyranoside at each drug concentration was calculated. The drug concentration, in which 50% uptake of methyl α-D-glucopyranoside (IC50 value) was inhibited, was calculated using a statistical plot. The results are shown in table 6. [Table 6] Test Example 2 Ensave for inhibitory effects on human SGLT2 activity 1) Cloning and construction of the vector expressing human SGLT2 The cDNA library was prepared for PCR amplification by reverse transcription from the total RNA devoid of human kidney (Ori gene) using oligo -dT as a primer. Using this cDNA library as a template, the DNA fragment encoding 2 to 2039 bp of human SGLT2 was amplified by PCR method (ACCESS: M95549, M95299), which was reported by RG Wells and associates, and inserted into the multiple cloning site of pcDNA3.1 (-) (Invitrogen). The sequence of Inserted DNA corresponded perfectly to the previously reported sequence. 2) Establishment of cell line stably expressing human SGLT2 The expression vector of human SGLT2 was digested by Let I be in linear DNA. Linear DNA was transfected into CHO-K1 cells by means of lipofection (Effectene Transfection Reagent: QIAGEN). Neomycin-resistant cell lines were selected by culture in a medium containing G418 (1 mg / mL, LI FE TECHNOLOGI ES), and subsequently the activity against the uptake of methyl-aD-glucopyranoside was measured by the method described later. The cell line, which showed the highest uptake activity, was selected and designated as CS2-5E. CS2-5E cells were cultured in the presence of G418 at 200 μg / mL. 3) Measurement of the inhibitory activity against the uptake of methyl-aD-glucopyranoside (a-MG) CS2-5E cells were seeded in a 96-well culture plate at a density of 3 X 1 O4 cells / tank and cultured for 2 days, and they were used in the capture assay. A mixture of unlabelled (Sigma) and 14C-labeled A-MG (Amersham Pharmacia Biotech) was added to the uptake buffer (pH 7.4; containing 140 mM of sodium chloride, 2 mM of potassium chloride, 1 mM of chloride calcium, 1 mM magnesium chloride, 10 mM 2- [4- (2-hydroxyethyl) -1-piperazinyl] ethane sulfonic acid and 5 mM of tris (hydroxymethyl) aminomethane) in a final concentration of 1 mM. A test compound was dissolved in dimethyl sulfoxide, and subsequently adequately diluted with distilled water. The solution of the test compound was added to the uptake buffer containing 1 mM of α-MG, and was designated as a measuring regulator. For the control group, the measurement regulator was prepared without any test compound. To measure basal uptake, a basal uptake measurement regulator containing 140 mM chlorine chloride was prepared in place of sodium chloride. After removing the culture medium from the CS1 -5-1 1 D cells, 180 μl of the pretreatment regulator (the basal uptake buffer without a-MG) was added to each well and incubated at a temperature of 37 °. C for 10 minutes. After repeating the same treatment, the pre-treatment regulator was removed. To each deposit was added 75 μL of the measuring regulator or the basal uptake regulator was added and added and incubated at a temperature of 37 ° C for 1 hour. After removing the measuring regulator, the cells were washed twice with 180 μL per wash buffer reservoir (the basal uptake buffer containing 10 mM unlabeled a-MG). Cells were solubilized through 75 μL per 0.2 mol / L deposit of sodium hydroxide. The cell lysates were transferred in PicoPlacas (Packard), and subsequently 150 μL of MicroScint-40 (Packard) were added and mixed. Radioactivity was measured by means of the TopCount micro-scintillation counter (Packard). HE adjusted 100% or the difference between the uptake in the control group and the basal uptake, and the uptake of methyl α-D-glucopyranoside at each drug concentration was calculated. The drug concentration, in which 50% uptake of methyl α-D-glucopyranoside was inhibited (IC 50 value), was calculated using a statistical plot. The results are shown in table 7. [Table 7] Industrial Applicability The fused heterocyclic derivatives represented by the general formula (I) above of the present invention, pharmaceutically acceptable salts and prodrugs thereof exert an inhibitory activity in human SGLT and can suppress the increase in blood glucose level or decrease the level of blood glucose, inhibiting the absorption of carbohydrates such as glucose in the small intestine, or inhibiting the reabsorption of glucose in the kidney. Accordingly, the present invention can provide excellent agents for the prevention or treatment of a disease associated with hypergiukaemia such as diabetes, postprandial hyperglycemia, glucose intolerance, diabetic complications, obesity or the like.

Coenzyme A reductase of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor , a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a sequestrant of bile acid, a sodium / bile acid cotransporter inhibitor, an inhibitor of cholesterol ester transferase protein, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, a receptor antagonist of angiotensin II, an endothelin conversion enzyme inhibitor, an endothelin receptor antagonist, an agent diuretic, a calcium antagonist, a vasodilation antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, an uricosuric agent and a urinary alkalinizer. 26. A human SGLT inhibitor as described in claim 9, characterized in that it comprises the combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, a insulin secretion enhancer, a

Claims (25)

1. R E I V I N D I C A C I O N S 1. A fused heterocyclic derivative represented by the following general formula (I): wherein: one of R and R4 represents a group represented by the general formula: [in the formula R5 and R6 independently represent a hydrogen atom, a hydroxy group, a halogen atom, a C6-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 group alkoxy, a C 2-6 alkenyloxy group, a C 1-6 alkylthio group, a C 2-6 alkenylthio group, a halo (C 1-6 alkyl) group, a halo (C 1-6 alkoxy) group, a halo group (d-6) alkylthio), a hydroxy (C 1-6 alkyl) group, a hydroxy (C 2-6 alkenyl) group, a hydroxy (C 1-6 alkoxy) group, a hydroxy group (d-6 alkylthio), a carboxy group, a carboxy group (C? -6 alkyl), a carboxy (C2-6 alkenyl) group, a carboxy group (C? -6 alkoxy), a carboxy (C1-6 alkylthio) group, an alkoxycarbonyl group, a C2 group. 7 alkoxycarbonyl (C 1-6 alkyl), a C 2-7 alkoxycarbonyl group (C 2-6 alkenyl), a C 2-7 alkoxycarbonyl group (C 2-6 alkoxy), a C 2-7 alkoxycarbonyl group (d-6 alkylthio), a C 1-6 alkylsulfinyl group, a d 6 alkylsulfonyl group, -UVWN (R 7) -Z, or any of the substituents of (i) al (xxviii) found later, which may have 1 to 3 substituents selected from the following substituent group on the ring; (i) a C6-10 aryl group, (ii) C6-? 0 aryl-O-, (iii) C6-? or aryl-S-, (iv) a C6-? or aryl (C1-6 alkyl), (v) a C6 -? or aryl group (C? -6 alkoxy), (vi) a C6-? or aryl group (C1-6 alkylthio), (vii) a group heteroaryl, (viii) heteroaryl-O-, (x) heteroaryl-S-, (x) a heteroaryl group (C 1-6 alkyl), (xi) a heteroaryl group (C 1-6 alkoxy), (xii) a group heteroaryl (C 1-6 alkylthio), (xiii) a C 3-7 cycloalkyl group, (xiv) C 3-7 cycloalkyl-O-, (xv) C 3-7 cycloalkyl-S-, (xvi) a cycloalkyl group (C 1 - 6 alkyl), (xvii) C3-7 cycloalkyl (C1-6 alkoxy), (xviii) a C3-7 cycloalkyl group (d-6 alkylthio), (xix) a heterocycloalkyl group, (xx) heterocycloalkyl-O-, (xxi) heterocycloalkyl-S-, (xxii) a heterocycloalkyl group (C 1-6 alkyl), (xxiü) a heterocycloalkyl group (d-6 alkoxy), (xxiv) a heterocycloalkyl group (d. 6 alkylthio), (xxv) an aromatic cyclic amino group, (xxvi) an aromatic cyclic amino group (C 1-6 alkyl) or (xxvii) an aromatic cyclic amino group (C 1-6 alkoxy), (xxviii) an aromatic cyclic amino group (C 1) -6 alkylthio), J represents a d-6 alkylene group, which may have a hydroxy group, or a C2-6 alkenylene group; U represents -O-, -S-, or a simple link, provided that minus one of V and W is not a simple bond when U is -O- or -S- V represents a C1-6 alkylene group, which may have a hydroxy group, a C2-6 alkenylene group or a single bond; W represents -CO-, -SO2-, -C (= NH) - or a single bond; Z independently represents a hydrogen atom, a C2-7 alkoxycarbonyl group, a C6-? Or aryl group (C2-7 alkoxycarbonyl), a formyl group, -RA, -CORB, -SO2RB, -CON (Rc) RD, - CSN (RC) RD, -SO2NHRA or -C (= NRE) N (RF) RG; R7, RA, Rc, and RD independently represent a hydrogen atom, a d-6 alkyl group, which may have from 1 to 5 substituents selected from the following substituent group β, or any of the following substituents of (xxix) al ( xxxii) which may have from 1 to 3 substituents selected from the following substituent group; (xxix) a C6 -? or aryl group, (xxx) a heteroaryl group, (xxxi) a C3-7 cycloalkyl group, or (xxxii) a heterocycloalkyl group, or Z and R7 link together with the surrounding nitrogen atom for forming an aliphatic cyclic amino group, which may have from 1 to 3 substituents selected from the following substituent group; or Rc and RD link together with the surrounding nitrogen atom to form an aliphatic cyclic amino group which may have from 1 to 3 substituents selected from the following substituent group; RB represents a C2-7 alkoxycarbonyl group, a C1 -6 group alkylsulfonylamino, a C6-? or arylsulfonylamino, a d-6 alkyl group, which may have from 1 to 5 substituents selected from the following substituent group β, or any of the following substituents (xxxiii) to (xxxvi) which may have from 1 to 3 substituents selected from next group to substituent; (xxxiii) a C6-1 or aryl group, (xxxiv) a heteroaryl group, (xxxv) a C3-7 cycloalkyl group, or (xxxvi) a heterocycloalkyl group, RE, RF, and RG independently represent a hydrogen atom, a cyano group, a carbamoyl group, a C2-7 acyl group, a C2-7 alkoxycarbonyl group, a C6-? or aryl (C2-7 alkoxycarbonyl), a nitro group, a C6_6 alkylsulfonyl group, a sulfamide group, a carbamimidoyl group, or a C1_6 alkyl group, which may have from 1 to 5 substituents selected from the following group ß substituent; or RE and RF link together to form an ethylene group; or RF and RG bond together with the surrounding nitrogen atom to form an aliphatic cyclic amino which may have any substituent selected from the following substituent group; Q represents -d-6 alkylene-, -C2-6 alkenylene-, -C2-6 alkynylene-, -d-6 alkylene-O-, -C1-6 alkylene-S-, -O-C1-6alkylene, -SC -? - 6 alkylene-, -d-6 alkylene-O-C1-6 alkylene-, -C1-6 alkylene-Sd-β-alkylene-, -CON (R8) -, -N (R8) CO-, -C1 -6 alkylene-CON (R8) - or -CON (R8) -C1 -6 alkylene-; R8 represents a hydrogen atom or a C1-C6 alkyl group; ring A represents a C6-10 aryl group or a heteroaryl group] and the others represent a hydrogen atom, a hydroxy group, an amino group, a halogen atom, a C1 -6 alkyl group, a d-6 alkoxy group , a cyano group, a carboxy group, a C2-7 alkoxycarbonyl group, a carbamoyl group, a mono- or di (C-? 6 alkyl) amino group, a halo (C1-6 alkyl) group, a hydroxy group (C? -6 alkyl), a cyano group (C 1-6 alkyloyl), a carboxy group (C 1-6 alkyl), a C 2-7 alkoxycarbonyl group (C 1-6 alkyloyl), a carbamoyl group (C 1-6 alkyl), an amino group (d-6 alkyl), a mono- or di- (C 1-6 alkyl) amino group (C? _6 alkyl), a halo (d-6 alkoxy) group, a hydroxy (d-6 alkoxy) group, a carboxy group (C-6 alkoxy), a C2-7 alkoxycarbonyl group (d-6alkoxy), a carbamoyl group (d-6alkoxy), an amino group (d-6alkoxy), a mono- or di (d-) group 6 alkyl) amino (Ci-6 alkoxy), a C3-7 cycloalkyl group, a C3-7 cycloalkyloxy group, a C3-7 cycloalkyl group (d-6 alk ilo), or a C3-7 cycloalkyl (C1-6 alkoxy) group; R2 and R3 independently represent a hydrogen atom, a hydroxy group, an amino group, a halogen atom, a d-6 alkyl group, a C1_6 alkoxy group, a cyano group, a carboxy group, a C2-7 group alkoxycarbonyl, a carbamoyl group, a mono- or di- (C 1-6 alkyl) amino group, a halo (C 1-6 alkyl) group, a hydroxy (C 1-6 alkyl) group, a cyano (C 1-6 alkyl) group, a carboxy group (C -? - 6 alkyl), a C 2-7 alkoxycarbonyl group (C-6 alkyl), a carbamoyl group (C 1-6 alkyl), an amino group (C 1-6 alkyl), a mono or di group (C 1-6 alkyl) amino (d-6 alkyl), a halo group (C 1-6) alkoxy), a hydroxy group (C 1-6 alkoxy), a carboxy group (C-6 alkoxy), a C 2 -alkoxycarbonyl group (C 1-6 alkoxy), a carbamoyl group (C 1-6 alkoxy), an amino group (C 1-6) -6 alkoxy), a mono- or di (C1_6 alkyl) amino (d_6 alkoxy) group, a C3-cycloalkyl group, a C3-cycloalkyloxy group, a C3-7 cycloalkyl group (C1-6 alkyl), or a C3- group 7-cycloalkyl (C6-alkoxy); A1 represents O, S, or NR9; A2 represents CH or N; R9 represents a hydrogen atom or a C-? -6 alkyl group; G represents a group represented by a formula: or a formula: E1 represents a hydrogen atom, a fluorine atom or a hydroxy group; E2 represents a hydrogen atom, a fluorine atom, or a methyl group or a hydroxymethyl group; [substituent group a] a halogen atom, a hydroxy group, an amino group, a C 1-6 alkyl group, a C 1-6 alkoxy group, a halo (C 1-6 alkyl) group, a halo group (C? -6) alkoxy), a hydroxy (C1-6 alkyl) group, a group C 2-7 alkoxycarbonyl (C 1-6 alkyl), a hydroxy group (C 1-6 alkoxy), an amino group (d-6 alkyl), an amino group (d-6 alkoxy), a mono- or d- group (d- 6-alkyl) amino, a mono- or di-hydroxy (C? -6 alkyl) amino group, a C 1-6 alkylsulfonyl group, a C 1-6 alkylsulfonylamino group, a C? -6 alkylsulfonylamino group (C 1-6 alkyl) , a carboxy group, a C 2-7 alkoxycarbonyl group, a sulfamoyl group, and -CON (RH) R ', [substituent group β] a halogen atom, a hydroxy group, an amino group, a C 1-6 alkoxy group, a d-6 alkylthio group, a halo (d-6 alkoxy) group, a (d6 alkylthio) group, a (C1-6 alkoxy) hydroxy group, a hydroxy group (C-? 6 alkylthio), an amino group ( d-6 alkoxy), an amino group (d-6 alkylthio), a mono- or di (C 1-6 alkyl) amino group, a mono- or di [hydroxy (C 1-6 alky]] amino group, a ureido group, a sulfonamide group, a mono or di (d-6 alkyl) ureido group, a mono- or di [hydroxy (C1-6 alkyl)] ureido group, a mono- or di (C -6 alkyl) sulfonamide group,a mono- or di- [hydroxy] (C-? -6-alkyl)] -sulfonamide group, a C2-7-acylamino group, an amino group (C2.7 acylamino), a C -6 alkylsulfonyl group,. a C6-alkylsulfonylamino group, a carbamoyl group (d-6 alkylsulfonylamino), a carboxy group, a C2.7 alkoxycarbonyl group, -CON (RH) R ', and any of the following substituents of (xxxvii) a (xxxxviii ), which may have from 1 to 3 substituents selected from the above substituent group. (xxxvii) a group C6-? or aril, (xxxviii) C6-? 0 arilo-O-, (xxxix) a C6-? or aryl group (C? -6 alkoxy), (xxxx) a C6-? or aryl group (C1-6 alkylthio), a group (xxxxi) a heteroaryl group, (xxxxii) heteroaryl-O-, (xxxxii) ) a C3-7 cycloalkyl group, (xxxxiv) C3-7 cycloalkyl-O-, (xxxxv) a heterocycloalkyl group, (xxxxvi) heterocycloalkyl-O-, (xxxxvii) an aliphatic cyclic amino group or (xxxxviii) an aromatic cyclic group , RH and R1 independently represent a hydrogen atom or a C1-6 alkyl group, which may have 1 to 3 substituents selected from the following group? substituent; or both RH and R1 bond together with the surrounding nitrogen atom to form an aliphatic cyclic amino group which may have from 1 to 3 substituents selected from the following substituent group d; [group? substituent] a halogen atom, a hydroxy group, an amino group, a C-6 alkoxy group, a halo (C 1-6 alkoxy), a hydroxy (C 1-6 alkoxy), an amino group (C 1-6 alkoxy) ), a mono- or di (C6-6alkyl) amino group, a mono- or di- [hydroxy (C1-6alkyl)] amino group, a ureido group, a sulfamide group, a mono- or di- (C1-6alkyl) group ureido, a mono or di [hydroxy (C? -6 alkyl)] ureido group, a mono- or di (C1-6 alkyl) sulfamide group, a mono- or di- [hydroxy] (C-? --6 alkyl)] sulfamide group , a C2-7 acylamino group, an amino group (C2-7 acylamino), a d-6 alkylsulfonyl group, a C6-6 alkylsulfonylamino group, a carbamoyl group (d-6 alkylsulfonylamino), a carboxy group, a C2 group -7 alkoxycarbonyl, a sulfamoyl group, and -CON (RJ) R ?, [substituent group d] a halogen atom, a hydroxy group, an amino group, a C -? - 6 alkyl group, a C 1-6 alkoxy group, a halo (d-6 alkyl) group, a halo group (C 1 - 6 alkoxy) a hydroxy (d-6) alkyl group) a C2-7 alkoxycarbonyl group (C6-6 alkyl), a hydroxy (C1-6 alkoxy) group, an amino group (d-6 alkyl), an amino group ( C 1-6 alkoxy), a mono- or di (C? -6 alkyl) amino group, a mono- or di [hydroxy (d-6 alkyl)] amino group, a C 1-6 alkylsulfonyl group, a C? -6 group alkylsulfonylamino, a d-6 alkylsulfonyl amino group (C? -6 alkyl), a carboxy group, a C2-7 alkoxycarbonyl group, a sulfamoyl group, and -CON (RJ) R ?, R and R? independently represent a hydrogen atom or a C -? - 6 alkyl group, which may have any of 1 to 3 substituents selected from a hydroxy group, an amino group, a mono- or di- (C 1-6 alkyl) amino group, a C 2-7 alkoxycarbonyl group, and a carbamoyl group; or both RJ and R? they bond together with the surrounding nitrogen atom to form an aliphatic cyclic amino group which may have any of 1 to 3 substituents selected from a hydroxy group, an amino group, a mono- or di- (C 1-6 alkyl) amino group, a d-6 alkyl group, a hydroxy (d-6 alkyl) group, a C 2-7 alkoxycarbonyl group, a C 2-7 alkoxycarbonyl group (C 1-6 alkyl), and a carbamoyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
2. 2. A fused heterocyclic derivative as described in claim 1, characterized in that Q represents a methylene group, an ethylene group, -OCH2-, -CH2O-, -SCH2-, or -CH2S-, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
3. 3. A fused heterocyclic derivative as described in claim 2, characterized in that Q represents an ethylene group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
4. 4. A fused heterocyclic derivative as described in claim 2, characterized in that Q represents a methylene group or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
5. 5. A fused heterocyclic derivative as described in claim 1, characterized in that R5 and R6 independently represent a hydrogen atom, a hydroxy group, a halogen atom, a C1-6 alkyl group, a C2-6 alkenyl group , a C 2-6 alkynyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 1-6 alkylthio group, a C 2-6 alkenylthio group, a halo (C 1-6 alkyl) group, a halo group ( d-6 alkoxy), a halo group (C 1-6 alkylthio), a hydroxy group (d-6 alkyl), a hydroxy group (C 2-6 alkenyl), a hydroxy group (C 1-6 alkoxy), or a hydroxy group (C 1-6 alkylthio), or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
6. 6. A fused heterocyclic derivative as described in any one of claims 1 to 5, characterized because, wherein ring A represents a benzene ring or a pyridine ring, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
7. 7. A fused heterocyclic derivative as described in any one of claims 1 to 6, characterized in that, wherein G represents a group represented by the formula: , or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
8. 8. A pharmaceutical composition comprising as an active ingredient, a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
9. 9. A human SGLT inhibitor comprising as an active ingredient a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. 1 0.
10. A human SGLT inhibitor as described in claim 9, characterized in that the SG LT is SG LT1 and / or SGLT2; eleven .
11. A human SGLT inhibitor, as described in claim 9, characterized in that it is an agent for the inhibition of postprandial hypergiukaemia.
12. 12. A human SGLT inhibitor as described in claim 9, characterized in that it is an agent for the prevention or treatment of a disease associated with hypergiucemia.
13. 13. A human SGLT inhibitor as described in claim 12, characterized in that the disease associated with hyperglycemia is a disease selected from the group consisting of diabetes, glucose intolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia , suffering from lipid metabolism, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia and gout.
14. 14. A human SGLT inhibitor as described in claim 9, characterized in that it is an agent for inhibiting the progression of glucose intolerance in diabetes in a subject.
15. 15. A pharmaceutical composition as described in claim 8, characterized in that the dosage form is a sustained release formulation
16. 16. A human SGLT inhibitor, as described in claim 9, characterized in that the dosage form is a sustained release formulation
17. 17. A method for the inhibition of postprandial hypergiucemia, which comprises administering an effective amount of a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
18. 18. A method for the prevention or treatment of a disease associated with hypergiukaemia, wherein the method comprises administering an effective amount of a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically salt acceptable of them, or a prodrug thereof.
19. 19. A method for prevention or treatment as described in claim 8, characterized in that the disease associated with hypergiukaemia is a disease selected from the group consisting of diabetes, glucose intolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia and gout;
20. 20. A method for inhibiting the advance of glucose intolerance in subjects with diabetes, wherein the method comprises administering an effective amount of a fused heterocyclic derivative as described in any one of claims 1 to 7, or a salt pharmaceutically acceptable thereof, or a prodrug thereof. twenty-one . The use of a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof for the manufacture of a pharmaceutical composition for the inhibition of postprandial hypergiukaemia. 22. A use of a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with hypergiucemia. 23. Use as described in claim 22, characterized in that the disease associated with hyperglycemia is a disease selected from the group consisting of diabetes, glucose intolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, suffering from lipid metabolism, atherosclerosis, hypertension, congestive heart failure, edema, hyperuricemia and gout. 24. The use of a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof for the manufacture of a pharmaceutical composition for inhibition. of the advance of glucose intolerance in a subject with diabetes. 25. A pharmaceutical composition as described in claim 8, characterized in that it comprises the combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose uptake inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analog, a receptor antagonist of glucagon, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an inhibitor of dipeptidyl peptidase IV, a protein tyrosine phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose inhibitor -6-phosphatase, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, an inhibitor of hepatic gluconeogenesis, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, an analogue of Glucagon-like peptide-1, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, a formation inhibitor of advanced glycation end products, a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, a NF-kB inhibitor of transcription factor, a lipid protease inhibitor, a dipeptidase-acid bound inhibitor N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analog, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, -hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartic, an inhibitor of SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an inhibitor of dipeptidyl peptidase IV, a tyrosine phosphatase-1 B inhibitor of protein, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a kinase-3 inhibitor, glycogen synthase, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of formation of advanced glycation end products, a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, an NF-kB inhibitor antigen, a lipid protease inhibitor, an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analogue, a factor of epidermal growth, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl , a fibrate, a β 3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a receptor agonist thyroid hormone, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a receptor enhancer of low density lipoprotein, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, a cholesterol ester transferase protein inhibitor, an appetite suppressant, a conversion enzyme inhibitor of angiotensin, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin conversion enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, an agent of sympathetic blockade, a centrally acting anti-hypertensive agent, an a2-adrenoceptor agonist This is an antiplatelet agent, an inhibitor of uric acid synthesis, an uricosuric agent and a urinary alkalizer. 27. A method for the inhibition of postprandial hypergiucemia as described in claim 17, characterized in that it comprises administering in combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, a receptor kinase stimulant, insulin, a tripeptidyl peptidase II inhibitor, an IV inhibitor of dipeptidyl peptidase, a protein tyrosine-1 B protein phosphatase inhibitor, a glycogen phosphorylase inhibitor, a glycoprotein-6-phosphatase inhibitor, a fructose- bisphosphatase, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a peptide agonist -1 type glucagon, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product formation, a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, an N F-kB inhibitor of transcription factor, a lipid protease inhibitor, a dipeptidase-acid inhibitor linked by N-acetylated-a, a insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analog, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methyl-hydantoin, EG B-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a protein transfer inhibitor, microsomal triglycerides, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a cotransporter inhibitor of sodium / bile acid, an inhibitor of cholesterol ester transferase protein, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an enzyme inhibitor of endothelial conversion, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent , an inhibitor of uric acid synthesis, an uricosuric agent and a urinary alkalinizer. A method for the prevention or treatment of a disease associated with hyperglycemia as described in claim 18, characterized in that it comprises administering in combination with at least one member selected from the group consisting of an insulin sensitivity enhancer, an inhibitor of glucose uptake, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analog, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, an IV inhibitor of dipeptidyl peptidase, a phosphatase-1 B inhibitor protein tyrosine, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a kinase-3 inhibitor of glycogen synthase, a glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analog, an amylin agonist, an aldose reductase inhibitor, an inhibitor of formation of advanced glycation end products, a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, a NF-kB inhibitor of transcription factor, a lipid protease inhibitor an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analog , epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartics, a coenzyme reductase inhibitor A of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, an inhibitor of microsomal triglyceride transfer protein, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, an inhibitor of cholesterol ester transferase protein, a appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, an antagonist of calcium, a vasodilation antihypertensive agent, a sympathetic blocking agent, a centrally acting anti-hypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, an uricosuric agent and a urinary alkalinizer; 29. A method for the inhibition of progression of glucose intolerance in subjects with diabetes as described in claim 1, characterized in that it comprises administration in combination with at least one member selected from the group consisting of an enhancer of insulin sensitivity, a glucose uptake inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, an inhibitor of tripeptidyl peptidase II, an IV inhibitor of dipeptidyl peptidase, a protein tyrosine phosphatase-1 B inhibitor, a phosphorylase inhibitor of glycogen, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a peptide-1 glucagon type, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product formation , a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, a NF-kB inhibitor of transcription factor, a lipid protease inhibitor, a dipeptidase-acid bound inhibitor N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analog, epidermal growth factor, growth factor Nerve of nerves, a derivative of carnitine, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarreic, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a receptor enhancer of low density lipoprotein, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, a cholesterol ester transferase protein inhibitor, an appetite suppressant, an enzyme conversion inhibitor, angiotensin, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin conversion enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, an sympathetic block, a centrally acting anti-hypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalizer. 30. A use of (A) or a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof and (B) at least one member selected from the group consisting of insulin sensitivity enhancer, a glucose uptake inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, a stimulant insulin receptor kinase, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a tyrosine protein phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, an inhibitor of inhibitor fructose-bisphosphatase, a pyruvate dehydrogenase inhibitor, an inhibitor of hepatic gluconeogenesis, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a glucagon-like peptide-1 analog, an agonist of glucagon-like peptide-1, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product formation, a protein C kinase inhibitor, an acid receptor antagonist ? -aminobutyric acid, a sodium channel agonist, an NF-kB inhibitor of transcription factor, a lipid protease inhibitor, an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, an analogue of platelet-derived growth factor, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartic, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, an inhibitor of cholesterol absorption, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a low density lipoprotein receptor enhancer, a derivative of nicotinic acid, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, a cholesterol ester transferase protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, a receptor antagonist of angiotensin II, an endothelin conversion enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkanilizer, for the manufacture of a pharmaceutical composition for the inhibition of postprandial hypergiukaemia. 31 A use of (A) or a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof and (B) at least one member selected from group consisting of insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, a kinase stimulant insulin receptor, a tripeptidyl peptidase II inhibitor, an IV inhibitor of dipeptidyl peptidase, a protein tyrosine phosphatase-1 B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, an inhibitor of fructose-bisphosphatase, a pyruvate dehydrogenase inhibitor, an inhibitor of hepatic gluconeogenesis, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a glucagon-like peptide-1, a glucagon-like peptide-1 analog, an agonist of glucagon-like peptide-1, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product formation, a protein C kinase inhibitor, an acid receptor antagonist ? -aminobutyric acid, a sodium channel agonist, an NF-kB inhibitor of transcription factor, a lipid protease inhibitor, an inhibitor of dipeptidase-acid bound by N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analog, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-m ethylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarrheal, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor , probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, an inhibitor of squalene synthase, a low density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, a cholesterol ester transferase protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, a receptor antagonist of angiotensin II, an endothelin conversion enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, an uricosuric agent, and a urinary alkanilizer, for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with heperglycemia. 32. A use of (A) or a fused heterocyclic derivative as described in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a prodrug thereof and (B) at least one member selected from the group consisting of insulin sensitivity enhancer, a glucose uptake inhibitor, a biguanide, an insulin secretion enhancer, an SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, a stimulant insulin receptor kinase, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1 B inhibitor, a phosphorylase inhibitor of glycogen, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiro-initol, a glycogen synthase kinase-3 inhibitor, a peptide-1 glucagon type, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an inhibitor of advanced glycation end-product formation , a protein C kinase inhibitor, a? -aminobutyric acid receptor antagonist, a sodium channel agonist, a NF-kB inhibitor of transcription factor, a lipid protease inhibitor, a dipeptidase-acid bound inhibitor N-acetylated-a, an insulin-like immunodeficiency factor, a platelet-derived growth factor, a platelet-derived growth factor analog, epidermal growth factor, growth factor Nerve of nerves, a derivative of carnitine, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, an antidiarreic, cathartics, a coenzyme A reductase inhibitor of hydroxymethylglutaryl, a fibrate, a β3-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl transferase inhibitor, a squalene synthase inhibitor, a receptor enhancer of low density lipoprotein, a nicotinic acid derivative, a bile acid sequestrant, a sodium / bile acid cotransporter inhibitor, a cholesterol ester transferase protein inhibitor, an appetite suppressant, an enzyme-converting enzyme inhibitor, angiotensin, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin conversion enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilation antihypertensive agent, an sympathetic block, a centrally acting anti-hypertension agent, an a2-adrenoceptor agonist, an antiplatelet agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkanilizer, for the manufacture of a pharmaceutical composition for inhibiting the advancement of glucose intolerance in patients with diabetes. SUMMARY The present invention provides cyclic nitrogen-containing fused derivatives represented by the following general formula or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit excellent inhibitory activity in human SGLT and are useful as agents for prevention or treatment. of a disease associated with hypergiucemia such as diabetes, postprandial hyperglycemia, glucose intolerance, diabetic complications or obesity, in formula one of R1 and R4 represent a group represented by the following general formula (S) (wherein R5 and R6 represent H, OH, a halogen atom, etc., Q represents an alkylene group, etc., and ring A represents an aryl group, etc.), and the others represent H, OH, an amino group, etc .; R2 and R3 represent H, OH, an amino group, a halogen atom, and an optionally substituted alkyl group, etc.; A1 represents O, S, etc.; A2 represents CH or N; G represents a group represented by the following general formula (G-1) or (G-2) (E1 represents H, F or OH, and E2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof. & '" 10 -. 10 -O ^? '/ 0